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Background: Current recommendations for the self-management of SARS-Cov-2
disease (COVID-19) include self-isolation, rest, hydration, and the use of NSAID in case
of high fever only. It is expected that many patients will add other symptomatic/adjuvant
treatments, such as herbal medicines.
Aims: To provide a benefits/risks assessment of selected herbal medicines traditionally
indicated for “respiratory diseases”within the current frame of the COVID-19 pandemic as
an adjuvant treatment.
Method: The plant selection was primarily based on species listed by the WHO and EMA,
but some other herbal remedies were considered due to their widespread use in respiratory
conditions. Preclinical and clinical data on their efficacy and safety were collected from
authoritative sources. The target population were adults with early and mild flu symptoms
without underlying conditions. These were evaluated according to a modified PrOACT-URL
method with paracetamol, ibuprofen, and codeine as reference drugs. The benefits/risks
balance of the treatments was classified as positive, promising, negative, and unknown.
Results: A total of 39 herbal medicines were identified as very likely to appeal to the
COVID-19 patient. According to our method, the benefits/risks assessment of the herbal
medicines was found to be positive in 5 cases (Althaea officinalis, Commiphora molmol,
Glycyrrhiza glabra, Hedera helix, and Sambucus nigra), promising in 12 cases (Allium
sativum, Andrographis paniculata, Echinacea angustifolia, Echinacea purpurea,
Eucalyptus globulus essential oil, Justicia pectoralis, Magnolia officinalis, Mikania
glomerata, Pelargonium sidoides, Pimpinella anisum, Salix sp, Zingiber officinale), and
unknown for the rest. On the same grounds, only ibuprofen resulted promising, but we
could not find compelling evidence to endorse the use of paracetamol and/or codeine.
Conclusions: Our work suggests that several herbal medicines have safety margins
superior to those of reference drugs and enough levels of evidence to start a clinicalin.org September 2020 | Volume 11 | Article 5818401
Silveira et al. COVID-19 and Evidence-Based Phytotherapy
Frontiers in Pharmacology | www.frontiersdiscussion about their potential use as adjuvants in the treatment of early/mild common flu
in otherwise healthy adults within the context of COVID-19. While these herbal medicines
will not cure or prevent the flu, they may both improve general patient well-being and offer
them an opportunity to personalize the therapeutic approaches.Keywords: herbal medicine, coronavirus (2019-nCoV), COVID-19, benefit/risk assessment, respiratory diseasesINTRODUCTION
The outbreak of Coronavirus SARS-Cov-2 disease (COVID-19)
in Wuhan (China) in late 2019 and its Worldwide spread has
caused hundreds of thousands of deaths so far. As of July 2020,
the disease seems to be mostly affecting Europe and the
Americas. Most people infected with the COVID-19 virus will
experience mild to moderate respiratory illness and recover
without requiring special treatment. Older people and those
with underlying medical problems such as cardiovascular
disease, diabetes, chronic respiratory disease, and cancer are
more likely to develop serious illness (WHO, 2020a). Teens
and adults without underlying medical conditions are asked to
self-manage their symptoms in isolation with a minimum of
drugs (paracetamol, if fever is high) and lifestyle adjustments
(increased rest and hydration). However, most of the current
guidelines do not specifically advise on how to treat cough, one of
the main symptoms, which, apart from being very debilitating,
contributes to the spread of the virus.
There is not yet any evidence-based specific therapy for
COVID-19, and the real efficacy and safety of current therapeutic
approaches will need further scrutiny when enough multi-site
clinical data become available. The examples of ibuprofen and
hydroxychloroquine illustrate how clinical protocols may include
and/or exclude drugs in their therapeutic approaches based on
limited evidence (Kim et al., 2020; Sodhi and Etminan, 2020;
Taccone et al., 2020; Torjesen, 2020). Predictably, patients will
largely try to increase their well-being at least by self-administering
cough suppressing medication (natural or not) plus natural
medication or supplements to combat cold/flu symptoms. These
are readily accessible both in retail commerce and community
pharmacies. InEurope, there are severalherbalmedicines registered
under the European Directive 24/2004 for self-prescription (EU,
2004). Their labeling establishes that these medicines are indicated
for the treatment of common cold and flu symptoms based on
traditional use only.Weagree in thatCOVID-19 isnot the common
flu, but theWHO definition is clear in that it is a mild, self-limiting
condition and, therefore, fitting the boundaries of self-prescription,
moreover if the patients have not been tested for the virus (WHO,
2020a). In that sense, there is a need to clarify the real potential and
safety profile of herbalmedicines to scientifically substantiate future
recommendations on their benefits and risks of use them.
Therefore, the impetus of this work is twofold. First, it intends
to highlight which species may provide a more rational
phytotherapeutic choice to the disease and second to showcase
which plants can be a clinically compatible option as adjuvant
therapy for the self-management of common cold/flu symptoms byin.org 2otherwise healthy adults within the context of the COVID-
19 pandemic.
Clinical Background
Early COVID-19 symptoms include fever, dry cough, and
dyspnea, among other similar ones to other viral respiratory
diseases such as common flu (Rothan and Byrareddy, 2020).
Therefore, the diagnosis of COVID-19 based on anamnesis
remains problematic. In general, the incubation period is
around 15 days, but the reported range is 0 to 24 days (Bai
et al., 2020). SARS-Cov-2 presents a strong transmission capacity
(Zheng et al., 2020). To complicate matters further, there is a
significant number of asymptomatic patients (up to 60%) who
unknowingly contribute to the spread of the disease (Gao et al.,
2020; Kronbichler et al., 2020).
The clinical spectrum of the infection goes from mild upper
respiratory tract illness to the so-called ‘severe acute respiratory
syndrome’: respiratory failure, shock, and multiple organ failure
(Bai et al., 2020; Zhou et al., 2020); and may be accompanied by
fatigue, headache, diarrhea, and lymphopenia (Rothan and
Byrareddy, 2020), and high incidence of cardiovascular
symptoms (Zheng et al., 2020). Older people and those with
underlying medical problems such as cardiovascular disease,
diabetes, chronic respiratory disease, and cancer are more
likely to develop severe illness (WHO, 2020a).
The precise pathology of the disease is not yet clear, but seems
to include a systemic pro-inflammatory response, inducing
hemodynamic changes and, consequently, a predisposition to
ischemia and thrombosis (Tang et al., 2020; Zheng et al., 2020;
Zhou et al., 2020). A hallmark of the disease is the “cytokine
storm”, a massive cytokine and chemokine release due to an
uncontrolled dysregulation of the host immune defense that
causes loss of function of multiple organs (Catanzaro et al., 2020).
Preventative and Therapeutic Approaches
Due to the emergence of the propagation of the disease, Health
Systems have become overloaded, even having sufficient diagnostic
capacity and hospital facilities to handle such an outbreak. In the
most vulnerable regions, the COVID-19 epidemic effectively
paralyzes health systems at the expense of primary health care
(Velavan and Meyer, 2020). Some measures, such as lock-down of
communities, social distancing, and quarantine-type for those
suspected to be infected can, at least in part, slow the COVID-19
spread (Heymann and Shindo, 2020) and, so, enable the health
systems to cope. However, these measures are palliative, and people
tend to ignore them after a few days of isolation, mainly those in
disadvantaged and vulnerable communities.September 2020 | Volume 11 | Article 581840
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evidence-base for the best strategy to treat, mitigate, and
prevent the diseases. Currently, none of the approaches used is
evidence-based.
In the worldwide search for a response to the COVID-19
pandemic, news about “alternative remedies against COVID”
have been disseminated (ANSES, 2020; Nordling, 2020). As of
July 2020, the evidence-base for such treatments is often limited
if not non-existent. However, often strong, unsubstantiated
claims are made about the pros and cons of herbal medicines,
which will also result both in false hopes or strong fears of those
at risk or ill with COVID-19 (Brennen et al., 2020;
Guastalegname and Vallone, 2020; Thorp, 2020).
While some preparations have been claimed to be specifically
active, some commonly used medicinal plants are assessed here,
especially those on the WHO list of selected medicinal plants, as
adjuvant treatments. For example, Hensel et al. (2020), in their
recent work, state that extracts prepared with Echinacea species
(Asteraceae) have an important role with the immune system
due to their alkylamide interacting with the cannabinoid
receptors (Hensel et al., 2020). Additionally, curcumin, the
main constituent in Curcuma longa L. (Zingiberaceae), is
suggested as a potential clinical option for the treatment of
SARS-CoV-2 infection, due to its action in several steps of a
viral infection such as protease inhibition, cellular signalling
pathways modulation, among others (Zahedipour et al., 2020)
In another paper (Panyod et al., 2020), 11 medicinal plants
were discussed concerning their in vitro antiviral activity using
different models. Two species (Allium sativum L. and Zingiber
officinale Roscoe) mentioned in this study that had their in vitro
potential and immune capacity assessed, were also included in
our study. Moreover, in an elegant evidence-based analysis,
eighteen phytotherapeutic preparations were mentioned as
having some role in the clinical management of viral
respiratory diseases, showing different levels of immunological
response (Portella et al., 2020). Four plants mentioned in that
report [Echinacea purpurea (L.) Moench, Glycyrrhiza glabra L.,
Sambucus nigra L., and Scutellaria baicalensis Georgi] were also
included in our study.
The rationale used in our study was to include, mostly, species
known in the Americas and Europe and those already more
widely available for the management of respiratory conditions
(Blumenthal, 2003; Edwards et al., 2015; Anheyer et al., 2018;
Langeder et al., 2020), mainly regarding the symptoms (cough,
pain, fever). We recognize that patients suffering from COVID-
19 are likely to seek such herbal medications. Complementing
other papers published on medicinal plants and their potential to
be used for COVID-19, we focused on the therapeutic potential
of 39 species, the limitations for their use, and their possible risks.
It must be strongly emphasized that this is not an assessment of
any mainline treatment for COVID-19 with such herbal
medicines. The focus is on assessing their potential as adjuvant
therapies to COVID-19. Although the listed herbal drugs
included herein have been used for a long time, the evidence
level of their action in the relief of mild respiratory symptoms
varies, and they are pointed out here.Frontiers in Pharmacology | www.frontiersin.org 3The Frame of the Problem
• Apart from a handful of antiviral drugs with limited efficacy,
there is only symptomatic therapy for influenza.
• There is no specific therapy for COVID-19.
• There are several herbal medicines recognized by various
Health Authorities for the treatment of flu, its symptoms, and
other respiratory disorders.
• Health authorities in Europe and the Americas have warned
the population against taking any natural/herbal medicines/
supplements. They sustain this advice on theoretical potential
effects on the immune system due to unspecific anti-
inflammatory effects in early stages, facilitating the infection
as well as potential immunostimulation, contributing to the
aggravation of the “cytokines storm”. As of today, there is no
clinical backup for such strong recommendations other than
trying to prevent unspecific herb-drug interactions should the
patient need emergency care.
• There is a significant OTC use for these herbal medicines,
and a realistic prospect is that patients will self-administer
them to increase their well-being.Aims
To apply a decision-making framework to provide a benefits/
risks assessment for selected herbal medicines traditionally
indicated for “respiratory diseases” within the current frame of
the COVID-19 pandemic.METHODS
For a treatment to be recommended as adjuvant therapy for
respiratory diseases in the context of COVID-19, we here
determine that the treatment is effective and that its expected
benefits outweigh its potential risks to patients. Briefly, this
assessment is informed by the body of evidence about each
treatment’s safety and efficacy retrieved in a literature search. This
assessment is also informed by a number of other factors, including
the severity of the underlying condition and how well patients’
medical needs are addressed by currently available therapies
(“reference drugs”). The decision also reflects current applicable
laws, regulations, and healthcare recommendations, taking into
consideration the uncertainty associated with COVID-19.
Selection of Herbal Medicines
A search was conducted, considering herbal medicines traditionally
used to relieve cold and flu symptoms. The criterion used to limit
the investigation, and to grant minimal evidence of efficacy was that
the species, linked to the chosen indications, must be listed at least in
one of the following organizations: World Health Organization
Monographs (WHO); European Medicines Agency (EMA);
European Scientific Cooperative on Phytotherapy; ANVISA
(Brazilian Pharmacopoea, Brazilian Pharmacopoea Herbal
Medicines Formulary, Brazilian Pharmacopoea Herbal Medicines
Mementum), Ministry of Health of Chile, Ministry of Health ofSeptember 2020 | Volume 11 | Article 581840
Silveira et al. COVID-19 and Evidence-Based PhytotherapyCuba, Ministry of Health of Colombia, and Government of Canada.
Several South American Countries use the Brazilian Pharmacopeia
documents as a reference, so they are also covered within this
search. Based on these documents, a list of target species was
prepared to establish a search of clinical evidence for the given
indication. We refer to these as “herbal medicines” as they are
endorsed by Scientific and/or Regulatory committees.
We also included some species which are not listed in
monographs based on their significant widespread use in the
self-management of respiratory diseases. Some of them are also
linked to food uses. We refer to these as “herbal remedies”.
We did not consider species that have given rise to major
safety concerns (such as Ephedra sp.) and species which are only
indicated for relieving mucous phlegm. Furthermore, we do not
assess multi-herbal preparations.
Decision-Making Framework
To assist our decision-making and/or the benefits/risks
assessment of herbal medicines, we adopted some of the
procedures described in many qualitative or semi-quantitative
guidelines to conduct a benefit-risk assessment (PROTECT,
2020). They consist of a step-by-step approach to follow for
good decision-making practice and to increase transparency.
Descriptive frameworks are usually general, and most of theFrontiers in Pharmacology | www.frontiersin.org 4time, reiterate common sense. Our framework is inspired by the
PrOACT-URL method (EMA, 2011c).
The main decision-making elements that we considered for
this work are:
A. Frame the problem. The appearance of early/mild respiratory
symptomsduring the pandemic including fever, cough, catarrh,
aches, and pains, nasal congestion, runny nose, sore throat,
cough, sneezing (= Condition) in adults otherwise healthy
(= Target Population). The patient did not have a test or was
negative for COVID-19, but continues at risk of infection
(= Uncertainty). The patient uses herbal medicines alone or
with drugs (= Treatment, main or adjuvant). The patient
experiences relief of upper respiratory symptoms within 1-2
weeks (= Favorable effect). The treatment interferes with
hospital/emergency treatment in case of severe acute
respiratory syndrome (Unfavorable effects).
B. Set criteria for Favorable/Unfavorable effects. We followed the
“General Guidelines for Methodologies on Research and
Evaluation of Traditional Medicine-World Health
Organization” for clinical evidence (WHO, 2000) (Table 1).
We agreed on six key criteria for safety (Table 2).
C. Consider options to be evaluated against the treatment.
Currently available over-the-counter (OTC) medicationsTABLE 1 | Grading criteria for clinical evidence of the treatments.
Grade Evidence levels quality/Type of evidence Requirements
High Ia Evidence obtained from meta-analysis of randomized controlled trials
Ib Evidence obtained from at least one randomized controlled trial
Requires at least one randomized controlled trial as part of the body of literature of
overall good consistency addressing the specific recommendation.
Medium IIa Evidence obtained from at least one well-designed controlled study
without randomization
IIb Evidence obtained from at least one other type of well-designed
quasi-experimental study
III Evidence obtained from well-designed non-experimental descriptive
studies, such as comparative studies, correlation studies, and case-
control studies
Requires availability of well-conducted clinical studies with no randomization clinical
trials on the topic of recommendation
Low IV Evidence obtained from expert committee reports or opinions and/or
clinical experience of respected authorities
Requires evidence from expert committee reports or opinions and/or clinical
experience of respected authorities. Indicates the absence of directly applicable
studies of good qualityAdapted from General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine World Health Organization (WHO, 2000).TABLE 2 | Grading criteria for safety level of the treatments and its evidence.
Grade Type of adverse effects Evidence levels quality/Type of evidence*
High A. Other/s than those listed below (B-F). May include allergies, contraindication in
pregnancy/lactation, children/elderly, GI disturbances, etc.
Ia Evidence obtained from pharmacovigilance data
Ib Evidence obtained from medically reviewed drug
monographs/Patients information leaflets
Ic Evidence obtained from clinical trials
Medium B. Reported interactions which may affect cardiovascular and/or platelet function
C. Presence of compounds potentially able to theoretically produce any in the COVID-19
context (such as coumarins, salicin, ephedrine, etc.)
D. No adverse effects reported but known immunostimulant activities
II Evidence obtained from case reports or clinical practice/
well stablished use.
III Preclinical evidence in relevant experimental models.
Low E. Reported adverse effects which may affect the respiratory function
F. Reported interactions which may affect emergency treatments (anesthesia, mechanical
ventilation, etc.)
IV Recommendations from expert committee reports or
opinions of respected authorities.*Adapted from General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine World Health Organization (WHO, 2000).September 2020 | Volume 11 | Article 581840
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inflammatory drugs (NSAIDs) (ibuprofen, naproxen, etc.),
antipyretics (acetaminophen/paracetamol), and cough
medicines (dextromethorphan, codeine, etc.). They may be
taken as monotherapy or alternating therapies. Therefore,
one of each category (ibuprofen, paracetamol, and codeine)
was chosen to be evaluated based on the same criterion.
D. Assess the balance between favorable and unfavorable effects
and the associated uncertainty. All possible combinations of
clinical and safety grades lead to four possible results:
“positive”, “promising”, “negative”, and “unknown”. The
last two categories allowed for the inclusion of two
different degrees of uncertainty (Table 3).
E. Recommendation. See conclusions.Retrieval of Evidence and Grading
In the second step, we assessed the existing clinical evidence and
safety data of all shortlisted herbal medicines and remedies
through a bibliographic search, including PubMed, Web Of
Science, and other available sources, using the terms “<plant
name>” AND cough OR flu OR cold. Also, Cochrane, Drug.com,
governmental agencies (EMA, ANSES, and others) were used.
All possible combinations of clinical and safety grades lead to
four possible results: “positive”, “promising”, “negative”, and
“unknown”. The last two categories allowed for the inclusion
of two different degrees of uncertainty. Table 3 shows how the
consensus criteria were translated into a preliminary benefits/
risks assessment.
We are aware that for many herbal drug preparations,
preclinical evidence exists, and this is not considered in this
assessment since it cannot be translated directly into clinical
practice. However, such estimation might be of relevance to
unveil potential mechanisms of action only so in that case this
information was included.RESULTS
Options to Be Evaluated Against the
Criteria
Based on the defined parameters, three recommended drugs for
early symptoms of COVID-19 - codeine, ibuprofen, and
paracetamol - were evaluated.
Ibuprofen
Indications in the context of respiratory conditions. Fever,
pain, inflammation.Frontiers in Pharmacology | www.frontiersin.org 5Posology. Up to 2,400 mg a day in doses not bigger than 400
mg every 6 h.
Preclinical evidence. In vitro and in vivo studies showed
evidence of antipyretic and mild analgesic activities (Rainsford, 2015).
Clinical evidence. In a review on the effects of non-steroidal
anti-inflammatory drugs (NSAIDs) for treating pain or
respiratory symptoms (e.g., cough associated with the common
cold), the conclusion was NSAIDs are somewhat effective in
relieving the discomfort caused by cold. However, there is no
clear evidence of their effect in easing respiratory symptoms.
Therefore, the balance of benefits and risks needs to be
considered when using NSAIDs for colds (Kim et al., 2013).
There is an ongoing clinical trial in the UK with COVID-19
patients receiving a liquid ibuprofen formulation on top of
standard care (ClinicalTrials.gov, 2020). Overall, the clinical
evidence is High.
Safety. Side effects of ibuprofen include anemia, decreased
hemoglobin, eosinophilia, hemorrhage, vomiting, and
hypertension. Other side effects include upper gastrointestinal
hemorrhage, upper gastrointestinal tract ulcers, dizziness, and
dyspepsia. A comprehensive list of very common (10% or more)
to common (1% to 10%) adverse effects include nausea (up to
57%), vomiting (up to 22%), flatulence (up to 16%), diarrhea (up
to 10%); epigastric pain, heartburn, abdominal distress,
indigestion, dyspepsia, abdominal discomfort, constipation,
abdominal cramps/pain, fullness of GI tract, bloating, GI
hemorrhage, melena (1% to 10%) (Drugs.Com, 2020a).
However, regarding COVID-19 patients, there is not enough
evidence supporting the potential harmful effects (Sodhi and
Etminan, 2020). Overall, safety is Medium.
Specific warnings and precautions of use. Ibuprofen may
cause severe cardiovascular thrombotic events, myocardial
infarction, and stroke, which can be fatal. This risk may be
increased in patients with cardiovascular disease or risk factors
for cardiovascular disease. Ibuprofen is contraindicated for the
treatment of peri-operative pain in the setting of coronary artery
bypass graft (CABG) surgery. NSAIDs can also cause an
increased risk of serious gastrointestinal adverse events,
especially in the elderly, including bleeding, ulceration, and
perforation of the stomach or intestines, which can also be
fatal (McGettigan and Henry, 2011).
Overall assessment. According to well-established use,
ibuprofen may be useful in the symptomatic relief of respiratory
conditions by reducing fever and aches. However, there is only a
relatively low number of clinical studies, and meta-analyses do not
provide consistent evidence that ibuprofen is effective in reducing
symptoms and duration and prevention of the common cold.
Overall, the clinical evidence is High. Ibuprofen may have
antiplatelet activities; its safety may be considered Medium.
Codeine
Indications in the context of respiratory conditions. Cough.
Posology. Up to 360 mg a day in doses not bigger than 60 mg
every 4 h.
Preclinical evidence. Some in vitro, ex vivo, and in vivo studies
show evidence of anti-cough activity (Ohi et al., 2007; Cui
et al., 2019).TABLE 3 | Benefits/Risks Decision Consensus Criteria.
Clinical evidence
(Table 1)
Safety evidence
(Table 2)
Benefits/risks
Balance
High High Positive
High/Medium Medium Promising
Low High/Medium Unknown
High/Medium/Low Low NegativeSeptember 2020 | Volume 11 | Article 581840
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antitussive, the clinical evidence supporting this action is
controversial. A study, involving 91 adults presenting cough
associated with acute upper respiratory tract infection, showed
codeine statistically had the same effect than vehicle (syrup) in
controlling cough (Eccles et al., 1992). Overall, the clinical
evidence is Low.
Safety. Commonly reported side effects of codeine include
drowsiness, lightheadedness, dizziness, sedation, shortness of
breath, nausea, vomiting, sweating, and constipation. Other
possible effects include bronchospasm, laryngospasm, respiratory
depression; heartbeat irregularities, blood pressure changes,
syncope, itching, facial swelling, pruritus, urticaria, histamine
release; dry mouth, loss of appetite, nausea, vomiting, paralytic
ileus, toxic megacolon, anorexia, stomach cramps; miosis, blurred or
double vision; euphoria, dysphoria, unusual dreams, hallucinations,
insomnia, anxiety (0.1% to 1%); respiratory arrest, dyspnea;
flushing, hypotension, palpitations, circulatory depression, shock,
cardiac arrest, circulatory depression, bradycardia, tachycardia,
edema (Drugs.com, 2019). Overall, safety is Low.
Specific warnings and precautions of use. Death due
to respiratory depression has been reported in children
(Friedrichsdorf et al., 2013; Tobias et al., 2016). Moreover, codeine
can lead to opioid misuse, abuse, and addiction (Casati et al., 2012).
Overall assessment. According to established use, codeine
may be useful in the symptomatic relief of cough. However,
clinical studies and meta-analyses do not provide consistent
evidence that codeine is effective in treating cough. Overall, the
clinical evidence is Low. Due to the severe side effects, codeine
safety may be considered Low.
Paracetamol
Indications in the context of respiratory conditions. Fever, pain.
Posology. Up to 4 g a day in dose not bigger than 1 g every 6 h.
Preclinical evidence. Numerous in vitro and in vivo studies
show evidence of antipyretic and mild analgesic activities
(Graham et al., 2013).
Clinical evidence. Paracetamol (acetaminophen) did not show
any efficacy in flu, according to a clinical trial involving 80 patients
(Jefferies et al., 2016). In a systematic review, the authors concluded
that the data did not provide sufficient evidence to inform practice
regarding the use of acetaminophen for common cold in adults (Li
S. et al., 2013). Overall, the clinical evidence is Low.
Safety. Paracetamol (acetaminophen) is hepatotoxic (Athersuch
et al., 2018), and several side effects have been reported (Ishitsuka
et al., 2020), such as nausea (up to 34%), vomiting (up to 15%);
abdominal pain, diarrhea, constipation, dyspepsia and enlarged
abdomen (1% to 10%); anemia, postoperative hemorrhage (1% to
10%); rash, pruritus (1% to 10%); dyspnea, abnormal breath sounds,
pulmonary edema, hypoxia, pleural effusion, stridor, wheezing,
coughing (1% to 10%); cardiovascular effects (1% to 10%):
peripheral edema, hypertension, hypotension, tachycardia, chest
pain; metabolic alterations (1% to 10%): hypokalemia,
hyperglycemia; headache, dizziness (1% to 10%). Other side
effects: dystonia; muscle spasms, trismus (1% to 10%); insomnia,
anxiety (1% to 10%); oliguria (1% to 10%); pyrexia, fatigue (1% toFrontiers in Pharmacology | www.frontiersin.org 610%) (Drugs.com, 2020b). There are reported cases of deaths in flu
patients taking paracetamol (Stevenson et al., 2001). Overall, the
safety evidence is Low.
Specific warnings and precautions of use. Not indicated in
cases of liver disease and alcoholism (Drugs.com, 2020b).
Overall assessment. According to a well-established use,
paracetamol may be useful in the symptomatic relief of
respiratory conditions by reducing fever and aches (although a
relatively low number of clinical studies and meta-analyses do
not provide consistent evidence that paracetamol can reduce
symptoms and duration), and prevention of the common cold.
The clinical evidence may be considered Low or at best Medium.
It is known to be hepatotoxic, and a frequent incidence of
respiratory adverse effects may justify serious concerns and a
safety rating of Low.
Assess the Relative Importance of the
Decision Maker’s Risk Attitude Towards
Herbal Substance
Risk is inherent to any therapeutic intervention (herbal or not).
The level of risk of herbal interventions in adults experiencing
common flu symptoms without underlying conditions is very
low. According to WHO, COVID-19 is self-limiting and mild in
this segment of the population (WHO, 2020a). However, we took
extra care in integrating current health authorities’ advice with
current clinical evidence to emit our assessment.
Scientific and Clinical Data of Current
Herbal Therapy Referred to as Useful to
Relieve Symptoms Related to Respiratory
Conditions (Cold/Flu)
General warning: allergic reactions and gastrointestinal (GI)
disturbances are common adverse effects in all medicines and
apply to herbal ones. Their use in pregnancy and lactation,
babies, children, and the elderly, as well as patients with
known severe conditions, is to be individually assessed by a
registered healthcare professional.
The recommendations made here are for medicinal products
regulated by national authorities to ensure their quality and
safety. Other products may be unsafe due to contamination,
adulteration, and the presence of naturally occurring toxins in
levels above those permitted.
Allium sativum L. - Amaryllidaceae (Bulbs, Powder)
Indications in the context of respiratory conditions. Allium
sativum is indicated for respiratory disease, namely cold and
cough (CUBA, 2014; EMA, 2017b), and other symptoms related
to influenza (BRASIL, 2011). Other related indications of garlic
preparations (fresh, garlic powder) included diaphoretic,
antiseptic, bacteriostatic, and antiviral effects. It is also used to
treat chronic bronchitis and recurrent upper respiratory tract
infections (EMA, 2017b; El-Saber Batiha et al., 2020b).
Traditional indications. Allium sativum has been traditionally
used for alleviation of symptoms of the common cold in adults
and children over 12 years. Indeed, garlic is considered as aSeptember 2020 | Volume 11 | Article 581840
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symptoms. Moreover, the British Herbal Pharmacopoeia
considers that garlic products are indicated for recurrent colds
and whooping cough (BHMA, 1983).
Chemical composition. Sulfur compounds (allicin, mercaptan,
allyl methyl thiosulphinate, allyl methyl trisulphide, diallyl
disulfide, diallyl trisulfide, S-allyl cysteine sulphoxide, and
others), glucosides (sativoside B1, proto-degalactotigonin), amino
acids (alanine, arginine, aspartic acid, asparagine, histidine, proline,
alanine, valine), monoterpenoids (citral, geraniol, alfa and beta-
phellandrene and other), peptides, minerals, flavonoids, and
vitamins (Lanzotti, 2006; Omar and Al-Wabel, 2010). In the
presence of the enzyme alliinase, alliin will be converted to allicin
(1 mg alliin to be equivalent to 0.45 mg of allicin). Allicin is also the
precursor of other non-volatile products such as ajoenes or oligo-
and polysulphides (ESCOP, 2003a; Kovarovič et al., 2019).
Posology (based on traditional uses). Fresh garlic: 2.0–4.0 g
average daily dosage (EMA, 2017b). However, it is preferable to
use a commercial preparation with defined composition and an
adequate dose.
Preclinical evidence. This herbal medicine has been experimentally
proven to have antiviral activity. Among the viruses which are sensitive
to garlic extracts, are the Human Cytomegalovirus (HCMV), Influenza
B virus, Herpes simplex virus type 1, Herpes simplex virus type 2,
vesicular stomatitis virus, Parainfluenza virus type 3, Vaccinia virus,
and human Rhinovirus type 2 (Tsai et al., 1985; Mikaili et al., 2013).
Allicin-containing supplements can prevent attacks by the common
cold virus.
Clinical evidence. There is no clinical data to support garlic in
the treatment of upper respiratory infections, only in the
prevention and treatment of symptoms of the common cold
(Josling, 2001). Regarding the prevention or treatment of the
common cold, a Cochrane meta-analysis concludes that there is
insufficient clinical evidence (Lissiman et al., 2014); the sole study
retained for the analysis showed fewer days of illness in the garlic
group compared with the placebo group (Josling, 2001). Another
trial suggested that consuming the aged garlic extract could
reduce the severity of cold symptoms reported (Nantz et al.,
2012). Overall, the clinical evidence is High for cold.
Safety. Garlic preparations are generally considered to be safe
(EMA, 2016a). However, patients taking anticoagulation and/or
antiplatelet therapy should use garlic preparations with caution
because they may increase bleeding times (EMA, 2017b). Overall,
safety is Medium.
Specific warnings and precautions of use. Patients should
avoid concomitant use with anti-platelet drugs.
Overall assessment. Although Allium sativum preparations
have been used to relieve cold symptoms since ancient times,
there is no evidence this herbal medicine can relieve flu symptoms.
Whether it may indirectly provide anti-inflammatory and
soothing effects on the upper respiratory tract remains to be
seen. The clinical evidence may be considered High. Even
though garlic is known to have potential antiplatelet effects,
overall, it can be considered presenting Medium safety, due to
products with less than 0.6% allicin content do not appear to have
any such effects (Scharbert et al., 2007).Frontiers in Pharmacology | www.frontiersin.org 7Althaea officinalis L. - Malvaceae (Roots, Leaves)
Indications in the context of respiratory conditions. Althaea
officinalis is indicated for respiratory disease symptoms,
namely dry, irritable coughs, and irritations of oral and
pharyngeal mucosa (EMA, 2016c).
Chemical composition. Mucilage polysaccharides, such as
galacturonorhamnans (rhamnogalacturonan), arabinans,
glucans, arabinoglucans, mainly of acidic polysaccharides;
flavonoids (e.g., isoscutellarein, hypolaetin, kaempferol and
luteolin derivatives); phenolic acids; coumarin (scopoletin);
tannins (ESCOP, 2019; Kianitalaei et al., 2019).
Posology (based on traditional uses). 0.5–5.0 g in 150mlofwater
as amacerate, three times daily (EMA, 2016c).Marshmallow root’s
syrup is also a commonly used preparation in a daily dose of 2.0-
8.0 ml (ESCOP, 2019; Kianitalaei et al., 2019).
Preclinical evidence. This herbal medicine has been
experimentally proven for respiratory disease symptom,
namely, cough. The aqueous extract of marshmallow roots
inhibited the tracheobronchial smooth muscle contractions in
rats in a dose-dependent manner (Alani et al., 2015). The
antitussive effects of oral rhamnogalacturonan (50 mg/kg) were
evaluated against mechanically induced cough reflux in both
sexes of non-anesthetized cats. The polysaccharide significantly
reduced the number of efforts, cough frequency, and intensity of
cough attacks from laryngopharyngeal and tracheobronchial
areas (Nosalova et al., 2005). The antitussive effects of oral
syrup and the polysaccharide were tested against mechanically
induced cough of non-anesthetized cats in comparison with non-
narcotic antitussives (Nosal’ova et al., 1992).
Clinical evidence. Althaea officinalis preparations have been
trialed clinically for respiratory disease, and the following
symptom was evaluated: cough. In a randomized clinical study,
63 adults suffering from dry cough associated with angiotensin-
converting enzyme inhibitors ingested 20 drops, three times per
day, of either a marshmallow root preparations or a placebo, for
four weeks. The severity of the cough in the marshmallow group
was significantly reduced (Rouhi and Ganji, 2007). In one clinical
trial on 822 patients with dry cough associated with pharyngeal
irritation, the efficacy, tolerability, and satisfaction of A.
officinalis root aqueous extract in the form of lozenges and
syrup was evaluated. Althaea officinalis root aqueous extract
improved the symptoms of dry cough within 10 min with very
good tolerability. There were only three minor adverse events in
the syrup group (Fink et al., 2017). Overall, the clinical evidence
is High for cough.
Safety. No toxicity was reported at the indicated doses (EMA,
2016b). Overall, safety is High.
Specific warnings and precautions of use. The absorption of
other drugs taken simultaneously may be retarded due to the
presence of mucilage. As a precautionary measure, all
preparations with A. officinalis should not be taken 30 min to
1 h before or after intake of other drugs/minerals/vitamins. The
macerate should be used immediately after preparation
(EMA, 2016b).
Overall assessment. Althaea officinalis preparations can
suppress cough and diminish irritation through anti-September 2020 | Volume 11 | Article 581840
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traditional use as cold therapy in the context of upper respiratory
conditions is not backed up by robust clinical data, but the
evidence allows us to infer a potential use in the relief of early
symptoms of COVID-19. The clinical evidence may be
considered High, and as no severe concerns are reported for
this herbal medicine, it can be rated as High safety.
Andrographis paniculata (Burm.f.) Nees -
Acanthaceae (Leaves, Aerial Parts)
Indications in the context of respiratory conditions:
Andrographis paniculata is indicated for respiratory disease,
namely common cold, influenza type, and other upper
respiratory tract infections, cough, and fever (WHO, 2002). It
is often included in multi-herbal preparations, which are not
assessed here [aside from the combination with Eleutherococcus
senticosus (Rupr. & Maxim.) Maxim.].
Chemical composition. Relevant secondary metabolites are
diterpenes like andrographic acid, their glucosides
(deoxyandrographolide-19b-D-glucoside) and dimers (bis-
andrographolides A, B, C, and D) and labdane diterpenoids
like andrographolide, neoandrographolide; flavonoids
(methoxylated flavones, flavanones, chalcones); steroids (b-
sitosterol (Koteswara Rao et al., 2004; Akbar, 2011; Dai et al.,
2019; Hanh et al., 2020). Andrographolides are considered the
active metabolites and chemical markers of this species.
Posology (based on traditional uses). 1–3 g as a decoction,
three times daily (WHO, 2002). However, it is preferable to use a
commercial preparation with defined composition and an
adequate dose.
Preclinical evidence. This herbal medicine has been
experimentally proven for respiratory disease, based on a
mouse-model for influenza (an adapted H1N1 strain PR8A/
PR/8/34). Treatment with andrographolide decreased the virus
loads and the expression of the inflammatory cytokines. Also,
diminished lung pathology and overall survival rate (Ding et al.,
2017). Anti-inflammatory and immunomodulatory properties of
the extract of A. paniculata and andrographolide have been
linked to the increasing proliferation of lymphocytes and the
production of IL-2 and inhibition of the tumor cell proliferation
immune system (Rajagopal et al., 2003; Kumar et al., 2004). Also,
diminished lung pathology and overall survival rate (Ding et al.,
2017). Neoandrographolide has in vivo anti-inflammatory effects
(Panossian et al., 2002). Andrographolide and a standardized
registered fixed combination of A. paniculata extract SHA-10
and E. senticosus extract SHE-3 showed an in vitro effect on the
activation and proliferation of immune-competent cells as well
on the production of key cytokines and immune activation
markers (Dai et al., 2019; Kim et al., 2019). A range of anti-
inflammatory effects has been reported on diverse disease targets
for A. paniculata and key constituents (Dai et al., 2019; Kim
et al., 2019).
Clinical evidence. This herbal medicine has been trialed
clinically for cold symptoms. Three systematic reviews pointed
to the beneficial effects and safety of Andrographis for relieving
symptoms of acute respiratory tract infections and shorteningFrontiers in Pharmacology | www.frontiersin.org 8time to the symptom (Kligler et al., 2006; Akbar, 2011). The most
recent study included 33 randomized controlled trials (RCT)
with 7175 patients. The results indicated that compared to usual
care, a shortening of the duration of symptoms including cough,
sore throat, and sick leave/time to resolution was observed.
Concerns were raised due to the low quality of many studies
and their heterogeneity (Hu et al., 2017; Hu et al., 2018). Overall,
the clinical evidence is High for cold and cough.
Safety. An assessment report of EMA concludes that while
‘there is a clear effect on some CYP isoenzymes, the available
acute, and reproductive toxicity and genotoxicity data support
the safety of Andrographis’ (EMA, 2014a). On the other hand,
the Australian Therapeutic Goods Administration (TGA)
highlighted the potential risks of severe allergic reactions
(TGA, 2015), which, however, seems to be of very limited
clinical concern. There are some preclinical indications of
immunomodulatory activities of unknown implications for the
COVID-19 cytokines storm. Overall, safety is Medium.
Specific warnings and precautions of use. Allergic reactions
may be of concern (TGA, 2015).
Overall assessment. Andrographis may be useful in the
symptomatic relief of respiratory symptoms, especially in terms
of alleviating the symptoms of uncomplicated upper respiratory
tract infections. Its traditional use as cold therapy in the context
of upper respiratory conditions is not backed up by robust
clinical data, but the evidences allow to infer a potential use in
the relief of early symptoms of COVID-19. The clinical evidence
may be considered High, and as although no severe concerns are
reported, this herbal medicine may exert immunomodulatory
activities so can be cautiously rated as Medium safety.
Commiphora molmol Engle [syn. Commiphora
myrrha (T.Nees) Engl.] and Other Commiphora sp. -
Burseraceae (Air-Dried Oleo-Gum Resin Exudate)
Indication in the context of respiratory conditions. Commiphora
molmol is indicated symptoms of respiratory disease, namely
mild inflammation of pharyngeal mucosa (WHO, 2007). Other
related symptoms are cough, anti-inflammatory (Akbar, 2020);
supportive treatment for tonsillitis (WHO, 2007; Barnes et al.,
2012; ESCOP, 2014).
Chemical composition. Sesquiterpenes (furanoeudesma1,3-
diene and lindestrene as the major components) (Marongiu
et al., 2005).
Posology (based on traditional uses). It is preferable to use a
commercial preparation with a defined composition, such as a
tincture (0.5–5 ml in 150 ml of water for rinsing or gargling three
times daily) (WHO, 2007).
Preclinical evidence. This herbal medicine has not been
experimentally proven for symptoms of respiratory disease.
Although C. molmol has been used as a remedy since ancient
times (Akbar, 2020), so far, only a few studies on anti-inflammatory
or antinociceptive action can be found. An ethanol extract from the
resin (at the doses of 100 mg/kg and 200 mg/kg, p.o.) presented
analgesic and anti-inflammatory activities in mice. In the swelling
paw test, the effect of the extract (100 mg/kg, p.o.) was similar to
indomethacin (10 mg/kg, i.p.) (Su et al., 2011).September 2020 | Volume 11 | Article 581840
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been trialed clinically for respiratorydisease, only for inflammation.
A standardized extract of C. molmol (curzerene 17.93%,
furanoeudesma-1,3-diene 27.44%, lindestrene 9.08%) was
evaluated about the anti-nociceptive effect. The volunteers (89
men and 95 women), presenting headache, fever-dependent pain,
joint pain, muscle aches, lower back pain, or menstrual cramps,
received extract (200 mg or 400 mg), or placebo, for 20 days.
According to this RCT, the extract presented a similar effect to some
frequently used drugs, such as diclofenac, ibuprofen, and
paracetamol, although requiring a longer time of use (20 days). In
the male group, the extract, at the dose of 400 mg, the effect was
significant against all the symptoms. For the female group, the
extractwas effectiveagainst lowbackpainand fever-dependentpain
at the doses of 200mg/day. Furthermore, no side effectwas reported
by any of the volunteers (Germano et al., 2017). Overall the clinical
evidence is High for pain associated with fever.
Safety. The safety of C. molmol is well established. There are
no known safety concerns from non-clinical or clinical data
(EMA, 2011d; EMA, 2018b). Overall, safety is High.
Specific warnings and precautions of use. Due to a uterine
stimulant effect (Vafaei et al., 2020), products containing C.
momol resin should be avoided in pregnancy and lactation
(EMA, 2011d). The concomitant use of C. molmol with
theophylline or cyclosporine A should be avoided (Al-Jenoobi
et al., 2015a; Al-Jenoobi et al., 2015b; EMA, 2018a).
Overall assessment. Commiphora molmol preparations seem
to have a supportive effect as antinociceptive and thus be useful
in the relief of respiratory symptoms. However, its effect is
evident only after a few weeks, thus exceeding the normal,
uncomplicated evolution of COVID-19. The clinical evidence
may be considered High. As no severe concerns are reported, this
herbal medicine safety can be rated as High.
Cymbopogon citratus (DC.) Stapf - Poaceae (Leaves)
Indications in the context of respiratory conditions. Cymbopogon
citratus is indicated for respiratory infections (CUBA, 2014).
Chemical composition. Essential oil (with geranial, neral and
myrcene as the major constituents) (Leclercq et al., 2000; Menut
et al., 2000; Pino and Rosado, 2000; Sidibé et al., 2001; Ali et al.,
2004; Kanko et al., 2004; Pérez et al., 2006; Rodriguez-Pérez et al.,
2006; Brito et al., 2011; Silva et al., 2014; Diop et al., 2017;
Soliman et al., 2017; Alam et al., 2018; Silva et al., 2018; BRASIL,
2019a); triterpenes (e.g., cymbopogonol; cymbopogone)
(Hanson et al., 1976); flavonoids (e.g., luteolin, apigenin,
kaempferol) (Cheel et al., 2005; Orrego et al., 2009; Costa
et al., 2015a; Costa et al., 2015b); phenolic acids (e.g., caffeic,
chlorogenic, ferulic acids and derivatives) (Tapia et al., 2007).
Posology (based on traditional uses). 1–2 g of dried leaves (or
4–5 g of fresh leaves) in 150 ml, up to three times daily (Carballo,
1995; Matos et al., 2001).
Preclinical evidence. Cymbopogon citratus has been
experimentally evaluated for fever. However, the evaluation of
the antipyretic activity of C. citratus herbal tea in rats (p.o. or i.p.)
did not result in body temperature reduction (Carlini et al.,
1986). On the other hand, other related experimental effects
include the anti-inflammatory potential of this species, mainlyFrontiers in Pharmacology | www.frontiersin.org 9the essential oil. The essential oil from C. citratus has been
reported to suppress inhibition of TNF-a-induced neutrophil
adherence, inducible nitric oxide synthase (iNOS), and other
lipopolysaccharides (LPS)-induced pathways, suppression of
COX-2 and peroxisome proliferator-activated receptor alpha
(PPAR-a) (Katsukawa et al., 2010; Francisco et al., 2013).
Another experiment (murine model of allergic asthma) showed
a standardized hexane extract of C. citratus led to the reduction
of inflammatory cells and eosinophils, as well as the expression of
NF-kB/p65, in mice sensitized by Bt-antigen (Machado et al.,
2015). Citral, the main substance in C. citratus essential oil,
presented antinociceptive and anti-inflammatory activity in mice
(Quintans-Júnior et al., 2011).
Clinical evidence. This herbal medicine has been not trialed
clinically for respiratory disease. Overall, the clinical evidence
is Low.
Safety. Some reports considered C. citratus safe with no health
issues from its usage due to the acceptable concentration limit of
the essential oil compounds (Carlini et al., 1986; Ekpenyong
et al., 2015). Overall, safety is High.
Specific warnings and precautions of use. None
Overall assessment. This herbal medicine is widely used, and
although its profile fit as safety relief therapy for flu, the anti-
inflammatory effect on the respiratory tract of C. citratus
preparations could be useful in the symptomatic relief of
respiratory disease. The clinical evidence may be considered
Low. As no severe concerns are reported, this herbal medicine
safety can be rated as High.
Echinacea sp. (E. angustifolia DC., E. purpurea (L.)
Moench and E. pallida (Nutt.) Nutt. - Asteraceae
(Aerial Parts, Rootstock)
Indications in the context of respiratory conditions. This herbal
medicine is indicated for symptoms of respiratory disease,
namely, those associated with common cold (EMA, 2017c).
Echinacea preparations are widely used to ‘prevent colds and
other respiratory infections, as immunostimulants and in
conditions associated with respiratory discomfort. The
European Medicine Agency (Herbal Medicinal Product
Committee, HMPC) granted registrations for Echinacea
purpurea (L.) Moench (purple coneflower) for a preventive
continuous use for maximal ten days, specifically excluding
pediatric populations and with autoimmune illnesses as a
contraindication (EMA, 2017a).
Chemical composition. Alkylamides, polysaccharides. Caffeic
acid derivatives serve as marker substances (e.g., echinacoside for
E. pallida root; cichoric acid for E. purpurea aerial parts) but are
not considered to be of therapeutic relevance (Edwards
et al., 2015).
Posology. It is essential to use a commercial preparation with
defined composition and an adequate dose. Preparations that
administer the extract to the upper respiratory tract (like
lozenges) may well be preferable over solid formulations.
Preclinical evidence. This herbal medicine has been not
experimentally proven for respiratory disease, namely cough,
fever, flu, cold (EMA, 2017a). In vitro studies were reported
against a range of respiratory viruses but for some preparationsSeptember 2020 | Volume 11 | Article 581840
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Vimalanathan, 2011). The immunomodulatory effects of a
standardized extract of Echinacea purpurea, as well as fractions
rich in chicoric acid, polysaccharide, and alkylamide, were
evaluated in rats. Phagocytic activity of alveolar macrophage was
increased with increasing concentrations of the Echinacea
components. Also, a trend of increase in TNF-a and NO release,
after in vivo LPS stimulation, by the alveolar macrophages was
observed. High concentration led to a release of cytokines (such as
TNF-a and IFN-g) in rat’s spleen macrophage (Goel et al., 2002).
Clinical evidence. Echinacea preparations have been trialed
clinically for flu and cold. However, the overall problem with the
assessment of the evidence refers to the variability of the
pharmaceutical preparations investigated in clinical studies
(Linde et al., 2006; Karsch‐Völk et al., 2014; David and
Cunningham, 2019). Therefore, a large number of clinical
studies, as well as a range of pharmacodynamics studies, have
been conducted, overall indicating at best a weak evidence for
benefits for treating colds. Several metanalyses failed to find any
evidence of clear benefits. Still, two RCT reported statistically
significant benefits for patients in terms treated with E. purpurea
and E. angustifolia preparations of both symptoms and reduced
duration of flu or cold (Linde et al., 2006; Karsch‐Völk et al.,
2014; David and Cunningham, 2019), thus qualifying for A (Ib).
Of note, one study showed no difference between an Echinacea
pallida preparation and oseltamivir (Raus ̌ et al., 2015). Overall,
the clinical evidence is High for cold and flu.
Safety. Echinacea preparations are generally considered to be
safe, although some allergic reactions have been recorded (EMA,
2017a). Interactions risks seem to be of no therapeutic concern
(Modarai et al., 2010). Although French Agency (ANSES)
postulated that echinacea, among other herbal medicines,
could interfere with the immune response in the context of
COVID-19 pandemic (ANSES, 2020), at this stage, there is no
evidence to support this and, more generally, herbal treatments
are not known to rigorously block inflammatory processes and to
negatively affect immune responses. Therefore, these concerns
seem to be a theoretical postulate which would require further
evaluation. While there are no clinical signals for interaction with
other medications, ANSES’s concerns might be linked to
theoretical interaction with immunosuppressants (such as
ciclosporin and methotrexate) due to an antagonistic effect
(Williamson et al., 2013). Overall, safety is Medium.
Specific warnings and precautions of use. Like all other
products discussed here, there is no evidence for specific
therapeutic benefits, and it is important to communicate this
to potential users. The safety concerns listed above need to be
kept in mind.
Overall assessment: Echinacea sp. may be useful in the relief
of respiratory symptoms by exerting a soothing effect on the
respiratory tract. Overall, a relatively large number of clinical
studies and a series of meta-analyses provide evidence that
Echinacea preparations seem to be efficacious both in the
treatment (reducing symptoms and duration) and prevention
of the common cold. The clinical evidence may be considered
High except for E. pallida. Although in the COVID-19 context,Frontiers in Pharmacology | www.frontiersin.org 10caution needs to be taken in order to avoid immunostimulation
in complications in later phases of the disease, this herbal
medicine safety can be rated as Medium.
Eucalyptus globulus Labill. - Myrtaceae (Leaves,
Essential Oil)
Indication in the context of respiratory conditions. Eucalyptus
globulus is indicated for symptoms of respiratory disease, namely
cough (WHO, 2002; BRASIL, 2011; EMA, 2013a). Other related
indications include respiratory antiseptic (CHILE, 2010) and
expectorant (COLOMBIA, 2008), due to the presence of 1-8-
cineol (Fischer and Dethlefsen, 2013; Salehi et al., 2019b).
Chemical composition. Essential oil (1,8-cineol as the major
component); phenolic acids (cafeic, ferulic acid, and derivatives),
tannins (gallic and protocatechuic acids), flavonoids (quercetin
derivatives) (Dixit et al., 2012; Sonker et al., 2017).
Posology (based on traditional uses). 1.5–3 g of dried leaves in
150 ml, up to four times daily (EMA, 2013a).
Preclinical evidence. This herbal medicine has not been
experimentally proven for symptoms of respiratory disease. In
vitro and in vivo studies with leaves extracts, essential oil, and
1,8-cineol are supportive for some ethnomedicinal use (Ross,
2001; Jun et al., 2013; Brezáni et al., 2018; Dhakad et al., 2018;
Galan et al., 2020); for example, the essential oil (300 mg/kg)
exerted an anti-inflammatory effect on LPS-induced bronchitis
in rats, inhibiting the airway mucin hypersecretion (Lu
et al., 2004).
Clinical evidence. Eucalyptus globulus essential oil
preparations have been trialed clinically for respiratory disease
(bronchitis, rhinitis), and the following symptoms were
evaluated: cough and throat irritation. In an aromatherapy
experiment with 48 students diagnosed with allergic rhinitis,
eucalyptus reduced coughing, itching sensation in the throat and
oral cavity, as well as other symptoms. After four weeks of
treatment, the volunteers related a reduction of the discomfort
provoked by rhinitis (Song and Kim, 2014). An RCT, involving
152 volunteers with acute non-purulent rhinosinusitis, was
carried out with 1,8-cineol, the main compound of eucalyptus
essential oil (capsules of 200 mg of oil or placebo, three times
daily). After four and seven days, the cineol group presented
better symptoms scores than the control group. Moreover,
inflammatory processes, such as bronchitis, pharyngitis,
tracheitis, conjunctivitis, were less frequent among the verum
group (Kehrl et al., 2004). Overall, the clinical evidence is
Medium for bronchitis and cough for the essential oil, while
for the herbal drug is Low.
Safety. In traditional doses, there is no report on the toxicity
of E. globulus. However, high doses can cause nausea, vomiting,
and diarrhea (WHO, 2002). In a preclinical assay of 1,8-cineol in
mice, this compound was classified as presenting low toxicity (Xu
et al., 2014). However, high doses can cause nausea, vomiting,
and diarrhea (WHO, 2002). However, in the cited clinical trial,
the essential oil and 1,8-cineol did not present a significant side
effect. Overall, safety is High.
Specific warnings and precautions of use. The use is
contraindicated for patients with hypersensitivity to the activeSeptember 2020 | Volume 11 | Article 581840
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under 30months of age due to 1,8-cineole containing preparations,
which can induce laryngospasm (EMA, 2013a). In rats, 1,8-cineol
induced CYP-450 activity and reduced the levels of amphetamine,
pentobarbital, andaminopyrine inplasmaorbrain (Jori et al., 1970).
Moreover, the usual precautions relevant to essential oils should be
taken into account.
Overall assessment. Eucalyptus globulus may be useful in the
relief of symptoms associated with upper respiratory infection by
exerting a soothing effect on the respiratory tract. However, even
though the extensive use of products containing eucalyptus
derivatives, more evidence is need on the impact in the
respiratory tract. The clinical evidence may be considered
Medium. Although there are concerns about the eucalyptus use
by babies, this herbal medicine safety can be rated as High.
Foeniculum vulgare Mill. – Apiaceae (Fruits)
Indications in the context of respiratory conditions. Foeniculum
vulgare is indicated for respiratory disease, namely cough
associated with cold and fever (EMA, 2007; WHO, 2007).
Chemical composition. Essential oil (trans-anethole,
estragole, and limonene as major components) (Singh et al.,
2006; Badgujar et al., 2014); stilbenes (e.g., foeniculosides X and
XI, cis- and trans-miyabenol) (De Marino et al., 2007);
flavonoids (e.g., eriodictyol, quercetin, and derivatives) (Parejo
et al., 2004; Faudale et al., 2008); and triterpenes and steroids
(e.g., oleanolic acid, 7a-hydroxycampsterol) (Parejo et al., 2004;
De Marino et al., 2007; Rather et al., 2016).
Posology. 1.5 to 2.5 g in 200 ml of boiling water (brew for
15 min) three times daily (EMA, 2007; WHO, 2007).
Preclinical evidence. This herbal medicine has been
experimentally proven for cough. The ethanol extract, as well as
the essential oil of F. vulgare presented analgesic and anti-
inflammatory activity in rats (Tanira et al., 1996; Özbek, 2005;
Him et al., 2008; Araujo et al., 2013; Elizabeth et al., 2014). The
aqueous and ethanolic extract and essential oil of F. vulgare were
evaluated about the myorelaxant activity using isolated guinea-pig
trachea, as a model to bronchodilatory effect. The ethanolic extract
and essential oil exert relaxant effects similar to those presented by
theophylline. The aqueous extract, on the other hand, presented a
contraction effect. The myorelaxant effect was not due to
inhibition of muscarinic and histamine H1 and/or stimulation
on b2-adrenergic receptors (Boskabady and Khatami, 2003).
Clinical evidence. Foeniculum vulgare has not been trialed
clinically for respiratory diseases. Overall, the clinical evidence
is Low.
Safety. Although essential oil of F. vulgare presents estragole
as one of the main components, and due to its genotoxic
carcinogenicity, the exposure to this compound should be kept
as low as possible (EMA, 2019), in the recommended herbal
preparation and posology, F. vulgare is considered safe. Overall,
safety is High.
Specific warnings and precautions of use. The safety of fennel
was long considered to be of no concern and importantly linked
to the long history of use as a medicine and food. The German
Commission E lists no risks. In recent years, concerns were
raised related to the content of estragole (methyl chavicol), whichFrontiers in Pharmacology | www.frontiersin.org 11is known as a potential carcinogen. No clinical reports of fennel’s
toxicity are known. The dose and the relevance of some studies
with pure estragole at high doses have been disputed. Overall, the
evidence is very limited, and there is no known reason for
concern (Edwards et al., 2015). Administration of different
doses of fennel essential oil reduced the intensity of oxytocin
and PGE2 induced contractions significantly (25 and 50 µg/ml
for oxytocin and 10 and 20 µg/ml for PGE2, respectively) (Ostad
et al., 2001). Fennel is a CYP3A4 inhibitor and can interfere in
the metabolism of several drugs (Subehan et al., 2006).
Overall assessment. Even though its profile fits as safety relief
therapy for cough in the context of upper respiratory affections,
therapeutic benefits are likely to be limited. The clinical evidence
is Low. This herbal medicine safety can be rated as High,
although the recommended dosage must be observed.
Glycyrrhiza glabra L. - Fabaceae (Roots)
Indication in the context of respiratory conditions. Glycyrrhiza
glabra is indicated for symptoms of respiratory disease, namely,
cough, sore throat (WHO, 1999; EMA, 2012a).
Chemical composition. Saponins (e.g., glycyrrhizin);
triterpenes (glycyrrhetinic acid); flavonoids (liquiritin,
rhamnoliquirilin, liquiritigenin, besides others); coumarins
(e.g., licoarylcoumarin); essential oil (Saxena, 2005; Öztürk
et al., 2017; Frattaruolo et al., 2019; El-Saber Batiha et al., 2020a).
Posology (based on traditional uses). 1.5 g of roots in 150 ml,
as herbal decoction two times daily (EMA, 2012a).
Preclinical evidence. This herbal medicine has not been
experimentally proven for cold symptoms. Other related
experimental effects are anti-asthma and antiviral. The anti-
asthma activity of licorice was proven in sensitized rats. A
crude hydroethanolic extract (100 mg/kg, p.o) exerted a similar
effect to prednisolone (10 mg/kg, p.o.) in mast cells
degranulation (Patel et al., 2017). Glycyrrhizin improved the
survival time of mice infected with the Influenza virus. Also,
inhibited the SARS-related coronavirus proliferation in vitro.
Glycyrrhizic acid inhibited the growth of the Influenza virus,
inflammatory cytokines, as well as the cytopathic effect of the
Respiratory Syncytial Virus (RSV) (Fiore et al., 2008).
Clinical evidence. Glycyrrhiza glabra preparations have been
trialed clinically for respiratory disease (asthma). An RTC,
involving 36 patients presenting chronic asthma, showed licorice
in a dose of 3.5 mg/kg in 200 ml water, three times daily, was able
to improve the pulmonary function’s parameter similarly to
prednisolone (0.15 mg/kg) as a single daily dose (Al-Jawad et al.,
2012). Overall, the clinical evidence is High for asthma.
Safety. Patients affected by hypertension, kidney diseases,
liver or cardiovascular disorders, or hypokalemia, should avoid
G. glabra (Nazari et al., 2017). On the other hand, licorice is
widely used in food preparation and, therefore, short term uses
seem of little concern in otherwise patients with no history of
major diseases. Overall, safety is High.
Specific warnings and precautions of use. In an in vitro
experiment, licorice ethanol extract inhibits CYP3A4 and
CYP2D6 (Budzinski et al., 2000; Pandit et al., 2011).
Overall assessment. Glycyrrhiza glabra is used for a long time
and can be useful in the relief of respiratory symptoms bySeptember 2020 | Volume 11 | Article 581840
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evidence can be considered as High. This herbal medicine safety
can be rated as High, although it should be avoided for some
risk groups.
Hedera helix L. - Araliaceae (Leaves)
Indication in the context of respiratory conditions. Hedera helix
is indicated for some symptoms of respiratory disease, namely
expectorant (a medicine that helps to bring up phlegm) for
productive (chesty) coughs (EMA, 2015a). Other related
indications include its actions as antispasmodic and in the
treatment of flu and fever (Bisset, 1994; Blumenthal et al.,
1998; Hong et al., 2015; Kruttschnitt et al., 2019).
Chemical composition. Flavonoids and other phenolics
(Urban, 1958; Trute and Nahrstedt, 1997; Al-Snafi, 2018);
polyacetylenes (falcarinol, dehydrofalcarinol) (Bohlmann et al.,
1961; Gafner et al., 1989); saponins (Elias et al., 1991; Crespin
et al., 1995; Yakovishin and Grishkovets, 2018); and essential oils
(b-caryophyllene, germacrene D, limonene, a- and b-pinene,
and sabinene as the main components) (Tucker and
Maciarello, 1994).
Posology. Pharmaceutical preparation with a defined
chemical profile and an adequate dose need to be used
(EMA, 2015a).
Preclinical evidence. This herbal medicine has been
experimentally proven for symptoms of respiratory disease,
namely productive cough (Hong et al., 2015; Pizzorno et al.,
2016). Other related experimental effects include acute and
chronic bronchitis, asthma, and pneumonia (Hong et al., 2015;
Pizzorno et al., 2016). The H. helix extract and isolated
compounds exerted a spasmolytic effect in isolated guinea-pig
ileum (Trute et al., 1997).
Clinical evidence. Hedera helix preparations have been trialed
clinically for respiratory diseases such as bronchial asthma, and
improvement of airway resistance, intrathoracic gas volume, and
forced expiratory volume were evaluated (Hofmann et al., 2003;
Guo et al., 2006; Holzinger and Chenot, 2011). However, despite
its established traditional use, very few controlled clinical studies
have been published. A randomized, double-blind trial was
carried was conducted with an H. helix standardized extract. A
total of 181 patients presenting acute cough was treated with 35
mg of the extract, three times daily, for 7 days. The group treated
with ivy extract showed a clinically relevant reduction in cough
score, the severity of symptoms associated with cough, and
bronchitis, in comparison with the control group. The
reduction of symptoms occurred in the first 48 h. of treatment.
The observed adverse effects were non-serious, mild, or moderate
severity and not related to the treatment (Schaefer et al., 2016). A
study involving 139 patients having acute bronchitis and
productive cough for at least three days, compared the
treatment using a standardized extract of H. helix and
acetylcysteine. No statistically differences were observed
between the treatments. Moreover, both treatments showed to
be safe and effective in children and adults (Kruttschnitt et al.,
2019; Kruttschnitt et al., 2020). Moreover, a review of the
treatment of upper respiratory tract infections identified 10
clinical trials, including three controlled trials (one of whichFrontiers in Pharmacology | www.frontiersin.org 12was placebo-controlled) and 7 non-randomized observational
studies (Holzinger and Chenot, 2011). Overall, the clinical
evidence is High for bronchitis and the common cold.
Safety. Although gastrointestinal reactions (EMA, 2015a) and
nausea, vomiting, and diarrhea have been listed among the
symptoms of overdose (Bisset, 1994), and although there might
be allergic reactions to the saponins, H. helix preparations are
generally considered to be safe. There was a minimal report of
adverse effects in 10 clinical trials, including three controlled
trials (one of which was placebo-controlled) and 7 non-
randomized observational studies (Holzinger and Chenot,
2011). Overall, the safety is High, and there are no reports to
infer that the preparations from the plant may interfere
negatively with the disease or NSAIDs.
Specific warnings and precautions of use. Hedera helix
preparations are contraindicated if the patient presents
dyspnea, fever, or purulent sputum. They should be used with
care in patients suffering from gastritis or gastric ulcers
(EMA, 2015a).
Overall assessment. Hedera helix preparations could be useful
in the symptomatic relief of respiratory diseases by exerting an
expectorant and anti-inflammatory effect on the respiratory
tract. In many countries, licensed preparations are regulated
for use in children. There is a robust body of clinical evidence
that can be considered as High. This herbal medicine safety can
be rated as High, due to the side effects that had been related only
in an overdose situation.
Justicia pectoralis Jacq. [syn. Dianthera pectoralis
(Jacq.) J.F.Gmel.] – Acanthaceae (Leaves)
Indications in the context of respiratory conditions. Justicia
pectoralis (chambá) is indicated for symptoms of respiratory
disease, as expectorant (BRASIL, 2011) and immunostimulant
(CUBA, 2014).
Chemical composition. Coumarins (mainly coumarin and
umbelliferone); flavonoids (e.g., quercetin, kaempferol,
swertisin, and derivatives) (Lino et al., 1997; Oliveira et al.,
2000); lignans (e.g., justicidin B) (Joseph et al., 1988).
Posology (based on traditional uses). 5 g in 150 ml of water as
an infusion (BRASIL, 2011).
Preclinical evidence. This herbal medicine has been
experimentally proven for symptoms of respiratory disease,
namely asthma. A standardized hydroalcoholic extract of J.
pectoralis presented inhibitory effects on the tracheal smooth
muscle of rats subjected to challenge with ovalbumin (OVA) in
an allergen model that reproduces many features of clinical
asthma such as bronchial hyper-reactivity. Administered by
gavage to sensitized rats after challenge with saline or OVA, the
extract of J. pectoralis decreased the exacerbated responsiveness of
rat trachea caused by the challengewith the sensitizing antigen. The
oral administration of the standardized extract reduced the
hyperresponsiveness in OVA-challenged trachea in preparations
stimulated with KCl (potassium chloride) or ACh (acetylcholine).
These effects on rat airways are possibly related to its anti-
inflammatory activity, as observed by its ability to significantly
inhibit the increase of the levels of TNF-a and IL-1b, pro-
inflammatory cytokines, in bronchoalveolar lavage of OVA-September 2020 | Volume 11 | Article 581840
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extract of J. pectoralis possesses potential anti-asthmatic properties
(Moura et al., 2017). In another study, the aqueous extract of J.
pectoralis was evaluated in sensitized guinea-pig. The crude extract
reduced the formation of histamine-inducedwheals.Moreover, the
extract was tested on guinea-pig tracheal contraction caused by the
cumulative dosing of histamine. Justicia pectoralis reduced
histamine-induced tracheal smooth muscle contractions
(Cameron et al., 2015).
Clinical evidence. Justicia pectoralis preparations have been
trialed clinically for cough in children only. The efficacy of
chambá syrup at 5% was evaluated in a randomized, double-blind
clinical trial, in 114 children presenting cough andother respiratory
symptoms. Chambá syrup was effective in relieving symptoms of
cough, nasal congestion, and rhinorrhea, as well as improving the
sleeping capacity of children when compared to placebo
(Nascimento, 2018).Overall, the clinical evidence isHigh for cough.
Safety. In traditional doses, there is no report about the
toxicity of J. pectoralis, including children.
Specific warnings and precautions of use. Due to the presence
of coumarin and derivatives, J. pectoralis use should be avoided
together non-steroidal anti-inflammatory or anti-coagulant
drugs (Wittkowsky, 2003). Overall, safety is High.
Overall assessment. Justicia pectoralis preparations might be
useful in the symptomatic relief of respiratory disease through
exerting an anti-inflammatory effect on the respiratory tract. The
clinical evidence may be considered High. Even though chambá
is known to have potential antiplatelet effects, overall, it can be
considered presenting Medium safety.
Magnolia officinalis Rehder & E.H. Wilson -
Magnoliaceae (Bark)
Indications in the context of respiratory conditions. Magnolia
officinalis is indicated for symptoms of respiratory disease,
namely cough, fever, and shortness of breath (WHO, 2009).
Chemical composition. Biphenyl neolignan derivatives:
magnolol (5,5’-diallyl-2,2’-dihydroxy biphenyl) and honokiol
(5,3’-diallyl-2,4’-dihydroxy biphenyl); isoquinoline-type alkaloids,
the majority of which are aporphine (N-methylcoxylonine, (S)-
magnoflorine, magnofficine, (R)-asimilobine, corytuberine,
anonaine, liriodenine) and benzylisoquinoline derivatives
(magnocurarine, (S)-tembetarine, lotusine, (R)-oblongine,
reticuline); essential oil (the major constituents are a-, b-, and g-
eudesmol) (Yan et al., 2013; Poivre and Duez, 2017).
Posology (based on traditional uses). 3-9 g of crude drug
(decoction) daily in divided doses (WHO, 2009).
Preclinical evidence. This herbal medicine has been
experimentally proven for asthma. Studies in animals and in
vitromodels have demonstrated multiple biological properties of
honokiol, including anti-asthma (through IL4 and IFN-NF-kB)
(Hong et al., 2018). Other related symptom studies are anti-
histamine (Shin et al. , 2001) and anti-HIV (human
immunodeficiency viruses) activities (Amblard et al., 2006).
Clinical evidence. Magnolia preparations have been trialed
clinically for asthma. Preliminary clinical studies showed the
benefits of magnolia for oral health (Campus et al., 2011). In non-Frontiers in Pharmacology | www.frontiersin.org 13comparative research, as add-on therapy in 148 patients with mild
to moderate asthma using inhaled corticosteroids, an extract of
Magnoliae flos had a beneficial effect on asthma control (Park et al.,
2012). Overall, the clinical evidence is Medium for asthma.
Safety. Magnolol and honokiol are the main ingredients of
magnolia bark and, therefore, were considered directly relevant
to evaluate the safety of the product. Full clinical monitoring,
including biochemical and hematological analysis, showed no
evidence of toxicity reported in subjects consuming magnolia
bark containing supplements at a dose of 750 mg/person/day
(approximately 15 and 60 mg/person per day of honokiol and
magnolol respectively) for 42 days (Garrison and Chambliss,
2006). According to other studies, safety and toxicity of magnolia
bark do not differ notably but may reflect insufficiencies of these
toxicity studies. Therefore, currently, studies of the mechanisms
of toxicity of magnolia bark are insufficient (Luo et al., 2019).
However, in the context of COVID-19, magnolol has been
identified as a potential enhancer of ACE2 expression (ANSES,
2020). Overall, the safety of M. oficinalis is Medium.
Specific warnings and precautions of use. None known.
Overall assessment. Magnolia bark has been used in Chinese
and Japanese traditional medicines for the treatment of asthma,
allergic disease, as well as for the alleviation of headaches,
muscular pain, and fever (Forrest, 1995; Lee et al., 2011). As
M. officinalis preparations are not clinically proven to provide
symptomatic relief of flu symptoms and its active principle
(magnolol) may enhance the entry SARS-CoV-2 virus into the
cell, the clinical evidence may be considered Medium and the
safety, in the COVID-19 context, Medium.
Malva sylvestris L. – Malvaceae (Leaves)
Indication in the context of respiratory conditions. Malva
sylvestris is indicated for respiratory disease, namely oral or
pharyngeal irritations and dry cough (BRASIL, 2011;
EMA, 2018d).
Chemical composition. Mucilages (mainly glucuronic and
galacturonic acids, rhamnose, galactose, fructose, glucose,
trehalose); flavonoids (e.g., malvidin, delphinidin, myricetin,
apigenin, kaempferol, genistein, and derivatives); tannins
(Farina et al., 1995; Paul, 2016); hydroxycinnamic acid and
derivatives; benzoic acid and derivatives; monoterpenes
(Cutillo et al., 2006).
Posology (based on traditional uses). 1.8 g in 150 ml as
infusion or decoction three times daily (EMA, 2018d).
Preclinical evidence. Malva sylvestris preparations have been
experimentally studied for cough. The anti-tussive activity of its
mucilage and isolated rhamnogalacturonan was evaluated in cats.
Both substances suppressed the cough reflex and decreased the
frequency of cough, especially in the laryngopharynx area, although
the polysaccharide was more active than mucilage (Nosalova et al.,
2005). Another study showed anti-inflammatory and analgesic
action through traditional pharmacological in vivo models
(Seddighfar et al., 2020). Mucilage seems to be responsible for
the cough suppressive activity of this species (Čapek et al., 1999).
Another experimental related activity is anti-inflammatory. Malva
sylvestris ethanolic extract presented anti-inflammatory activity inSeptember 2020 | Volume 11 | Article 581840
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of IL-1b in tissue challenged by TPA. Also, the extract and isolated
compounds inhibited myeloperoxidase activity. Malvidin-3-
glucoside presented inhibitory activity similar to dexamethasone
(Prudente et al., 2013). The aqueous extract can suppress the
expression of several pro-cytokine genes such as TNF-a, IL-1b,
COX-2, iNOS (Mirghiasi et al., 2015).
Clinical evidence.Malva sylvestris has not been trialed clinically
for respiratory disease. Overall, the clinical evidence is Low.
Safety. In traditional doses, there isnoreport about the toxicityof
M. sylvestris.However, high dosesmay cause nausea, vomiting and
diarrhea, nervous excitement, and insomnia (BRASIL, 2015a;
BRASIL, 2019b). Overall, safety is High.
Specific Warnings and precautions of use. In general, mucilage
can alter the absorption of some drugs (BRASIL, 2015a).
Overall assessment. Malva sylvestris has been traditionally
used as cough therapy and may be useful in the relief of COVID-
19 symptoms through exerting a soothing effect on the
respiratory tract. The clinical evidence may be considered Low,
but this herbal medicine is considered presenting High safety.
Mikania glomerata Spreng. and M. laevigata
Sch.Bip. ex Baker Asteraceae (Leaves)
Indications in the context of respiratory conditions. Mikania
glomerata is indicated for symptoms of respiratory disease,
namely cough, and as expectorant (BRASIL, 2011; BRASIL,
2017; BRASIL, 2018).
Chemical composition. Essential oil (germacrene D and
b-caryophyllene as the major components) (Ueno and Sawaya,
2019); coumarins (e.g., coumarin, trans-o-coumaric acid),;
phenolic acids (e.g., chlorogenic and caffeoylquinic acids)
(Lazzari Almeida et al., 2017); terpenoids and steroids (e.g.,
friedelin, ent-kaurenoic acid, ent-kaur-16(17)-en-19-oic acid,
ent-beyer-15(16)-en-19-oic acid, ent-15b-benzoyloxykaur16(17)-
en-19-oic acid, grandifloric acid, ent-cinnamoylgrandifloric acid,
ent-benzoylgrandifloric acid 17-hydroxy-ent-kaur-15(16)-en-19-
oic acid, stigmasterol, b-sitosterol) (Veneziani and Oliveira, 1999;
Bertolucci et al., 2013).
Posology (based on traditional uses). 3 g of dried leaves in
150 ml, as an infusion, 2 times daily. However, the use of dosage
forms, with defined composition, is recommended.
Preclinical evidence. This herbal medicine has been
experimentally proven for cough. The aqueous extract reduced
the contractile effect of histamine on the isolated guinea-pig
trachea and human bronchi (Moura et al., 2002). A fraction ofM.
glomerata ethanolic extract was evaluated through an allergic
pleurisy model in rats and resulted in the inhibition of leukocyte
infiltration (Fierro et al., 1999).
Clinical evidence. Mikania glomerata preparations have been
trialed clinically for one of the related diseases, namely cough.
This herbal medicine has been used in Brazil in respiratory
diseases, such as asthma, cough, and throat inflammation (Agra
et al., 2008; Brandao et al., 2009). A clinical trial sponsored by the
Brazilian government showed that the infusion of M. glomerata
(5, 10, and 15 g in 200 ml of water) had an unequivocal
bronchodilator action and evident dose-dependent antitussiveFrontiers in Pharmacology | www.frontiersin.org 14effect (Amaral et al., 2006). A randomized study involving 62
patients compared the bronchodilator effect of M. glomerata
syrup and salbutamol inhaler and found M. glomerata syrup did
not present effect (Garcia et al., 2020). However, the overall
problem with this study refers to the differences between the
investigated pharmaceutical preparations. Overall, the clinical
evidence is High for asthma, but Low for other types of cough.
Safety. Some non-clinical studies report its safety. Mikania
glomerata hydroalcoholic (70%) extract presented LD50 ~ 3000
mg/kg and did not produce any biochemical, hematological, and
morphological changes in mice (Santana et al., 2013). Moreover,
M. glomerata did not present genotoxicity, mutagenicity,
teratogenicity or antifertility activity (Sa et al., 2003; Sá et al.,
2006; Barbosa et al., 2012; Fulanetti et al., 2016). Doses above
those recommended may cause vomiting and diarrhea (Matos,
2000; BRASIL, 2011).Mikania glomerata syrup is included in the
Brazilian List of Essential Medicines, and so far, there are no
reported concerns relating to safety from the point of view
of pharmacovigilance.
Specific Warnings and precautions of use. Not to be used
while under treatment with NSAIDs. The use may interfere with
coagulation due to the presence of coumarin derivatives (Matos,
2000; Wittkowsky, 2003; BRASIL, 2011). Overall, safety
is Medium.
Overall assessment. Mikania glomerata is in the list of
essential medicine in Brazil for the symptomatic relief of cough
and asthma and has been prescribed for children for several years
without a pharmacovigilance report. Preclinical and clinical data
back up this indication, although guaco is not clinically proven to
provide relief of flu symptoms. The clinical evidence may be
considered High. Even though guaco is known to have potential
antiplatelet effects, overall, it can be considered presenting
Medium safety.
Ocimum gratissimum L. -Lamiaceae (Leaves)
Indication in the context of respiratory conditions. Ocimum
gratisssimum is indicated for symptoms of cold, influenza,
fever, asthma, bronchitis (WHO, 2002).
Chemical composition. Essential oil (eugenol, thymol, and
1,8-cineol as the major components) (Prabhu et al., 2009; Monga
et al., 2017); phenolics (quercetin and derivatives, luteolin and
derivatives, kaempferol and derivatives, catechin, epi-catechin,
cafeic acid); triterpenes (ursolic acid) (Prabhu et al., 2009;
BRASIL, 2015b; Siva et al., 2016; Monga et al., 2017).
Posology (based on traditional uses). 1-3 g in 150 ml of
boiling water, as an infusion, 3-4 times daily (BRASIL, 2019b).
Preclinical evidence. This herbal medicine has been
experimentally proven for cough. An aqueous extract of O.
gratissimum was evaluated in OVA-sensitized guinea-pig about
anti-tussive and anti-asthma activities. The aqueous extract did
not exert effect in pre-convulsive dyspnea; however, reduced in a
significant manner, the volume of tracheal liquid, although it did
not interfere in the fluid viscosity, and reduced in more than 80%
the number of cough episodes (Ozolua et al., 2016). Another
experimental related activity is anti-inflammatory. The essential
oil of O. gratissimum presented an antinociceptive effect in mice,September 2020 | Volume 11 | Article 581840
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Freire et al., 2013). A flavonoid-rich fraction of O. gratissimum,
in mice, presented anti-inflammatory activity, reducing the
number of the leucocytes in the peritoneum, and inhibited
iNOS, COX-2 (in the same degree than indomethacin). Also,
inhibited LPS-induced NO, IL-1b, and TNF-a production in
RAW 264.7 cells (Ajayi et al., 2017).
Clinical evidence. Ocimum gratissimum has not been trialed
clinically for respiratory diseases. Overall, the clinical evidence
is Low.
Safety. In traditional doses, there is no report about the
toxicity of O. gratissimum.
Specific Warnings and precautions of use. Due to the
presence of estragole, a naturally occurring genotoxic
carcinogen, O. gratissimum should be used for a short time, in
the recommended posology (EMA, 2005) (see also
Foeniculum vulgare).
Overall assessment. Its traditional use as cough therapy in the
context of upper respiratory conditions is not backed up by
clinical data profile, but its preclinical evidence and safety profile
may allow the potential use in the relief of early symptoms of
COVID-19. The clinical evidence is Low, and although there are
some concerns about the presence of estragole, in the traditional
doses, this herbal medicine is considered presenting High safety.
Pelargonium sidoides DC and/or Pelargonium
reniforme Curt. -Geraniaceae (Root)
Indications in the context of respiratory conditions. Pelargonium
sidoides is indicated for the common cold (EMA, 2018c), cough,
and bronchitis (COLOMBIA, 2008). Umkaloabo preparations
are available in some European Countries with a full marketing
authorization (e.g., Bulgaria, Czech Republic, Germany, Latvia)
or register as a traditional herbal medicinal product (e.g., Austria,
Hungary, Italy, The Netherlands, Poland, Spain, Sweden), and
are widely used for ‘acute bronchitis’ and other respiratory
infections’ (EMA, 2018c). Practically all research has been
conducted with the proprietary extract EPs 7630®. The species
originate from Southern Africa, and the term Umkaloabo is
claimed to be a fusion of two terms from Zulu (“Umkuhlune” -
coughing and fever; and “Uhlabo” = pain in the chest) (Heinrich
et al., 2018).
Chemical composition. Relevant key metabolites assumed to
be active are hydrolyzable tannins, (+)-catechin, gallic acid, and
methyl gallate, including some unusual O-galloyl-C-glucosyl
flavones., scopoletin, 6,8-dihydroxy-5,7-dimethoxycoumarin,
5,6,7-trimethoxycoumarin. Other coumarins, as well as,
quercetin 3-O-b-D-glucoside, myricetin, and other flavonoids
have been isolated from both species. Pelargonium sidoides
yielded some benzopyranones. Umckalin is only known from
P. sidoides (Maree and Viljoen, 2012); pelargoniins (an
ellagitannin) and the diterpene reniformin have been identified
in P. reniforme (Edwards et al., 2015).
Posology. Oral drops, tablets, and syrups are most commonly
used (EMA, 2018c). Commercial preparations with regulated
quality, a defined composition, and an adequate dose are
available on some markets globally.Frontiers in Pharmacology | www.frontiersin.org 15Preclinical evidence. This herbal medicine has been
experimentally proven for anti-viral activity. The commercial
extract EPs 7630® interfered in vitro with the replication of
different respiratory viruses, including human coronavirus
(Michaelis et al., 2011), Influenza virus (in vitro and in vivo)
(Theisen and Muller, 2012), and Rhinovirus isolated from
patients with severe asthma (Roth et al., 2019). EPs 7630 was
able to stimulate IFN-b in vitro, and gallic acid enhanced the
expression of iNOS and TNF-a (Kolodziej et al., 2003).
Clinical evidence. Pelargonium sidoides preparations have
been trialed clinically for cough. In a randomized, controlled
trial, involving 124 adults presenting acute bronchitis, were
treated with 30 drops of EPs 7630®, for seven days. The
treated group showed a significant improvement regarding the
Bronchitis Severity Score (BSS) compared with the placebo
group (Chuchalin et al., 2005). In a Cochrane review, the
efficacy of P. sidoides preparations in acute respiratory
infections in RCT was assessed and indicated that it might be
useful in the alleviation of symptoms of acute rhinosinusitis and
the common cold in adults. However, the authors also raised
concerns regarding the studies’ quality (Timmer et al., 2013).
Similarly, Schapowals’ meta-analyses of randomized, double-
blind, placebo-controlled trials concluded that it is useful in
the management of the common cold (Schapowal et al., 2019).
Overall, the clinical evidence is High for bronchitis and the
common cold.
Safety. Umkaloabo preparations are generally considered to
be safe, although gastrointestinal discomfort (stomach pain,
heartburn, nausea, or diarrhea) might occur with no major
concerns about interaction risks (Edwards et al., 2015).
However, due to the potential immunomodulatory activity,
overall, safety is Medium.
Specific warnings and precautions of use. As with all other
products discussed here, there is no evidence for specific
therapeutic benefits, and it is important to communicate this
to potential users. The safety concerns listed above need to be
kept in mind.
Overall assessment. Umkaloabo may be useful in the
symptomatic relief of respiratory symptoms through exerting a
soothing effect on the respiratory tract. A relatively large number
of clinical studies and a series of meta-analyses provide evidence
that Umkaloabo preparations seem to be efficacious both in the
treatment (reducing symptoms and duration) and prevention of
the common cold. However, it must be discontinued to avoid
immunostimulation in complications in later phases of the
disease. The clinical evidence is High, and this herbal medicine
is considered presenting Medium safety.
Pimpinella anisum L. – Apiaceae (Fruits)
Indications in the context of respiratory conditions. Pimpinella
anisum is indicated for cough and fever (WHO, 2009; CHILE,
2010) and as antispasmodic (WHO, 2009; CHILE, 2010;
BRASIL, 2011).
Chemical composition. Essential oil (trans-anethole as the
main compound) (Orav et al., 2008); chlorogenic acid
derivatives; flavonoids (orientin, vitexin, and others, coumarinSeptember 2020 | Volume 11 | Article 581840
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1991; Reichling and Galati, 2004; Abdollahi Fard, 2012).
Posology (based on traditional uses). 1,5 g of the dried fruits
in 150 ml, as an infusion, three times daily (BRASIL, 2011;
Barnes et al., 2012; EMA, 2013b).
Preclinical evidence. This herbal medicine has been
experimentally proven for cough. Aqueous and ethanol
extracts of P. anisum presented myorelaxant effect in isolated
tracheal chains of guinea-pig. The relaxant effect was similar to
promoted by theophylline. Interesting to note that the essential
oil did not present a significant effect (Boskabady and Ramazani-
Assari, 2001).
Clinical evidence. Pimpinella anisum preparations have been
trialed clinically for asthma. The bronchodilator activity of P.
anisum was evaluated in a study involving 50 patients presenting
bronchial asthma. The patients ingested tea (2 g in 200 ml of
water), twice a day for 40 days. All patients presented a reduction
of cough episodes after 21 days of treatment (from more than 6
episodes/day to none), as well as dyspnea and wheezing. Also, an
improvement in the breath-holding time and respiratory rate
was observed (Paheerathan, 2019). Overall, the clinical evidence
is High for asthma-related cough and Low for cough and fever.
Safety. In the traditional doses, there is no report about the
toxicity of P. anisum. However, allergic reactions can occur, for
example, rhinoconjunctivitis (Garcıá-González et al., 2002;
EMA, 2013b). Overall, safety is High.
Specific warnings and precautions of use. The concomitant
use with anti-coagulant drugs should be avoided due to the
presence of coumarins (Dinehart and Henry, 2005).
Overall assessment. Its traditional use as cough therapy in the
context of upper respiratory conditions is not backed up by
robust clinical data profile, but its safety profile allows for
potential use in the relief of early symptoms of COVID-19.
The clinical evidence may be considered High. Even though P.
anisum has potential antiplatelet effects, overall, it can be
considered presenting Medium safety.
Plantago lanceolata L. – Plantaginaceae (Leaves)
Indication in the context of respiratory conditions. Plantago
lanceolata is indicated for symptoms of respiratory disease,
namely cough, pharyngitis, and fever (CHILE, 2010). Other
indications include as demulcent, to reduce bronchial catarrh
and mild inflammation of the pharynx (Blumenthal et al., 1998;
ESCOP, 2003b; Wichtl, 2004; Boskabady et al., 2006a).
Chemical composition. Carbohydrates (Jiang et al., 2019);
flavonoids (apigenin, luteolin and their derivatives) (Haddadian
and Zahmatkash, 2014; Ferrazzano et al., 2015); iridoid
glycosides (aucubin and catalpol as the main ones) (EMA,
2014b; Lotter et al., 2017; Hasan et al., 2018); phenylethanoids
(Bahadori et al., 2020); saponins (Wichtl, 2004); tannins (Wichtl,
2004; Grigore et al., 2015); and essential oil (amyl vinyl carbinol
(E),4(3-oxo-2,6,6-trimethylcyclo-hex-2-en-1-yl)-3-buten-2-ol,
6-(3-hydroxy-1-butenyl)-1,5,5-trimethyl-7-oxabicyclo[4,1,0]
heptan-3-ol, and benzoic acid as major components) (Fons et al.,
1998; Bajer et al., 2016).
Posology (based on traditional uses). 2 g of leaves in 150 ml
boiling water, two to three times daily; 160-190 mg of powderedFrontiers in Pharmacology | www.frontiersin.org 16plant coated tablet or lozenges, maximum dose of 1.28 g daily
(EMA, 2014b). It is preferable to use a commercial preparation
with a defined composition and an adequate dose (EMA, 2014b).
Preclinical evidence. This herbalmedicine has been experimentally
proven for cough. An ethanol extract of P. lanceolata reduces the
number of coughs provoked by citric acid, in guinea-pig, in a similar
way to codeine (Boskabady et al., 2006a). Other experiments showed
that an ethanol extract of this species inhibited the barium-induced
contraction of guinea-pig isolated trachea (Fleer and Verspohl, 2007).
The pharmacological effects described in literature support both the
oral and oromucosal traditional use of herbal preparations of P.
lanceolata as a demulcent for the symptomatic treatment of oral
and pharyngeal mucosa irritation, associated to dry cough (Ortiz de
Urbina et al., 1994; Herold et al., 2003; Vigo et al., 2005; Hausmann
et al., 2007).
Clinical evidence. Plantago lanceolata has not been trialed
clinically for respiratory tract disorders. However, there is some
evidence in the literature for the traditional internal use of P.
lanceolata as a mucilage in the treatment of irritations of oral and
pharyngeal mucosa and associated dry cough (Wegener and
Kraft, 1999). However, data on this clinical assay are scarce.
Overall, the clinical evidence is Low.
Safety. Currently, there is a lack of toxicity and clinical safety
data for P. lanceolata, which warrants further investigation for
this plant. However, popular use points to hypersensitivity
reactions as the main side effects reported (Ozkol et al., 2012;
EMA, 2014b). Overall, the safety is High as there are no reports
to infer that the preparations may interfere with the disease
or NSAIDs.
Specific warnings and precautions of use. The topical use of
this plant is not recommended (EMA, 2011a; Ozkol et al., 2012;
EMA, 2014b). Plantago lanceolata pollen may cause hayfever,
especially if the plant is abundant in a region like in many
subtropical regions (Calabozo et al., 2001). Pla 11 has been
named the main allergen with IgE-binding capacity present in
this plant, although other IgE-binding proteins have also been
identified (Sousa et al., 2014). Treatment should not exceed one
week (EMA, 2014b). Minor diarrhea has also been reported
(EMA, 2011a).
Overall Assessment. Although P. lanceolata is not clinically
proven to provide symptomatic relief of flu symptoms, there are
enough preclinical evidences to allow the use of this herbal
medicine to relieve respiratory symptoms through exerting an
expectorant and anti-inflammatory effect. The clinical evidence
is Low, but this herbal medicine is considered presenting
High safety.
Platycodon chinensis (Jacq). A.DC. [syn. Platycodon
grandiflorus (Jacq.) A.DC.] – Campanulaceae (Roots)
Indications in the context of respiratory conditions. Platycodon
chinensis is indicated for cough (WHO, 1999). Other related
indications include expectorant (WHO, 1999); upper respiratory
infections; sore throat (PRC, 1992; Li Y. H. et al., 2013).
Chemical composition. Triterpene saponins (2%) (e.g.,
platycodigenin; polygalacic acid) ((Fu et al., 2011); steroids (d-
stigmasterol, a-spinasterin, betulin) (Wagner H. et al., 2015);
essential oil (He et al., 2013).September 2020 | Volume 11 | Article 581840
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decoction, daily (Chang and But, 1987).
Preclinical evidence. Platycodon chinensis has been
experimentally proven for cough and fever in mice (Oh et al.,
2010; Zhang et al., 2015). An aqueous extract from P. chinensis
presented anti-inflammatory activity in rats, in the carrageenan
model. The extract inhibited the production of cytokines and the
expression of COX-2 (Kim et al., 2006). Platycosides are
inhibitors of the production of IL-6, PGD2, LTC4, and b-Hex,
therefore presenting potential for allergy symptoms treatment
(Oh et al., 2010). Crude platycodin (80 mg/kg, p.o.) presented
expectorant activity, higher than ammonium chloride, in guinea-
pig. The author showed that crude platycodin also presented
analgesic and antipyretic activities in mice (Lee, 1975). Crude
platycodin presented anti-histaminic and anticholinergic effects
in guinea-pig, but not presented anti-serotonin or anti-
bradykinin effect (Takagi and Lee, 1972). Isolated platycodin D
and D3 presented anti-inflammatory and potential expectorant
activities. In rat and hamster tracheal surface epithelial cells, both
compounds increased mucin release. Platycodin D3 was most
active than ATP (mucin secretagogue) and ambroxol (mucolytic)
(Shin et al., 2002). A decoction of P. chinensis inhibited cough in
mice (Zhang et al., 2015).
Clinical evidence. This herbal medicine has been trialed
clinically for pneumonia. Two patients presenting pneumoniae
were treated with aqueous extract of P. chinensis and
acupuncture. Patients presented improvement in cough, phlegm,
and fever. Chest X-ray showed a decrease in lung infiltration (Kim
et al., 2001). Overall, the clinical evidence is Low.
Safety. Platycodon chinensis was considered safe in preclinical
evaluation. Platycodins present hemolytic activity; however, as
they are poorly absorbed, the oral ingestion in the suggested doses
seems to be safe (WHO, 1999). In the context of COVID-19,
overall, the safety is High, as there are no reports to infer that such
herbal preparations may interfere with the disease or NSAIDs.
Specific warnings and precautions of use. Radix Platycodi
reportedly depresses the central nervous system (CNS) (Lee,
1975; WHO, 1989). Therefore, the concomitant use of this herbal
medicine with alcohol or hypnotic and sedative drugs should be
avoided. Overall, the safety is Medium, but there are no reports
to infer that such herbal preparations may interfere with the
disease or NSAIDs.
Overall assessment. Based on traditional use, preparations
could be useful in respiratory symptoms relief, through exerting
an antitussive effect, although it is not backed up by robust
clinical data. The clinical evidence is Low, but this herbal
medicine is considered presenting High safety.
Polygala senega L. – Polygalaceae (Roots)
Indication in the context of respiratory conditions. Polygala
senega is indicated for cough (WHO, 2002; ESCOP, 2003b).
Other related indications include its actions as expectorant
bronchitis, emphysema, and catarrh of the upper respiratory
tract (Briggs, 1988; WHO, 2002; ESCOP, 2003b; Lacaille-Dubois
et al., 2020).
Chemical composition. Organic acids (salicylic acid and its
methyl ester) (Bradley, 1992; COE, 2008); monosaccharidesFrontiers in Pharmacology | www.frontiersin.org 17(Takiura et al., 1974; Takiura et al., 1975); oligosaccharides
(Ikeya et al., 1991; Saitoh et al., 1994); acylated glucosides
(Ikeya et al., 1991; Ikeya et al., 1994); triterpene saponins
(Tsukitani et al., 1973; Tsukitani and Shoji, 1973; Sakuma and
Shoji, 1981; Sakuma and Shoji, 1982; Bradley, 1992; Yoshikawa
et al., 1995b; Yoshikawa et al., 1995a; Yoshikawa et al., 1996;
Wichtl, 2004; COE, 2008; Evans, 2009); essential oils (Sakuma
and Shoji, 1982; COE, 2008), flavonoids; coumarins (Lacaille-
Dubois et al., 2020); and xanthones (Ikeya et al., 1994).
Posology (based on traditional uses). Herbal tea (dried root):
0.5–1.0 g three times a day (BHMA, 1983; Bradley, 1992). It is
preferable to use a commercial preparation with a defined
composition and an adequate dose.
Preclinical evidence. This herbal medicine has not been
experimentally proven for symptoms of respiratory disease.
However, the expectorant activity of the crude drug is due to
the constituent saponins, which produce local irritation of the
mucous membranes of the throat and respiratory tract. This
irritation stimulates an increase in bronchial secretions, thereby
diluting the mucus, reducing its viscosity and facilitating
expectoration (Boyd and Palmer, 1946; Misawa and Yanaura,
1980; Reynolds and Parfilt, 1996). Isolated saponins from roots
of this species were able to enhance anti-OVA specific IgG and
IgG2a in mice (Katselis et al., 2007).
Clinical evidence. Polygala senega preparations have not been
trialed clinically for respiratory diseases. French patent
mentioned that a triterpene acid isolated from P. senega
possesses anti-inflammatory action (Mitchell and Rook, 1979).
Another French Patent (Tubery P., Fr Demande Patent
2,202,683) claimed the fluid extract prepared with P. senega
could reduce the viscosity of phlegm in patients with
bronchiectasis (Barnes et al., 2012). However, data on this
clinical trial are limited. Overall, the clinical evidence is Low.
Safety. Generally, there is a lack of toxicity data and clinical safety
for Polygala species. Saponins of this species are usually irritant to
the gastrointestinal mucosa (Mitchell and Rook, 1979), and large
doses of the plant are reported to cause nausea, diarrhea, and
vomiting (Foster and Tyler, 1999; WHO, 2002). In the context of
COVID-19, overall safety is High, as there are no reports to infer
that the preparations may interfere with the disease or NSAIDs.
Specific warnings and precautions of use. Due to the lack of
toxicity data and potential risks associated with chronic ingestion
of this herbal medicine, the use by patients with gastric ulcer or
gastric inflammation should be avoided. Chronic exposure of the
intestinal mucosa to saponins may also inhibit active nutrient
absorption (Capasso et al., 2003).
Overall assessment. Senega preparations might be useful in
the symptomatic relief of respiratory symptoms through exerting
an antitussive effect. Although the clinical evidence is Low, this
herbal medicine is considered presenting High safety.
Polypodium vulgare L. – Polypodiaceae (Rhizomes)
Indication in the context of respiratory conditions. Polypodium
vulgare is indicated for symptoms of respiratory disease, namely
cough (EMA, 2008c).
Chemical composition. Flavonoids (Grzybek, 1976; Karl et al.,
1982); hydroxycinnamic acids (caffeic acid 4’-glucoside, 0.6% inSeptember 2020 | Volume 11 | Article 581840
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phytoecdysteroids (Arai et al., 1991; Yamada et al., 1992;
Marco et al., 1993; Coll et al., 1994; Reixach et al., 1996;
Messeguer et al., 1998; Simon et al., 2011); triterpenes (Devys
et al., 1969; Robinson et al., 1973; EMA, 2008b).
Posology (based on traditional uses). 4–5 g, as a decoction, 3–
4 times a day. Not to be taken for more than a week
(EMA, 2008c).
Preclinical evidence. This herbal medicine has been
experimentally proven for respiratory disease. A hydroalcoholic
extract presented a myorelaxant dose-dependent effect in rabbit
isolated tracheal preparation. The effect was cholinergic-like
(Naz et al., 2016). However, the expectorant and antitussive
effects of saponins are known (Hostettmann and Marston, 2005),
and the saponin in the fresh plant of polypody acts as a cough
suppressant (Høeg, 1984).
Clinical evidence. Polypodium vulgare has not been trialed
clinically for respiratory diseases. Overall, the clinical evidence
is Low.
Safety. Overall, the safety is High as there are no reports to
infer that the preparation from this plant may interfere with the
disease or NSAIDs.
Specific warnings and precautions of use. A mild laxative
effect may happen when this plant is used as expectorant (EMA,
2008c). Moreover, due to possible hypotensive and hypnotic
effects, patients should be aware of potential interactions
(Ulbricht et al., 2006).
Overall assessment. Polypodium vulgare preparations could
be useful in the relief of the respiratory symptoms, through
exerting an antitussive effect. Although the clinical evidence is
Low, this herbal medicine is considered presenting High safety.Potentilla erecta (L.) Raeusch. – Rosaceae
(Rhizomes, Roots)
Indications in the context of respiratory conditions. Potentilla
erecta is indicated for cough and symptomatic treatment of
minor inflammations of the oral mucosa (EMA, 2010;
ESCOP, 2013).
Chemical composition. Hydrolysable tannins (pedunculagin,
pentadigalloylglucose, agrimoniin, laevigatin B, tormentillin);
condensed tannins/proanthocyanidins ([4,6]-all-trans-bi-
(+)-catechin = procyanidin B6, [4,8]-2,3-trans-3,4-cis-bi-
(+)-catechin, [4,8]-all-trans-bi-(+)-catechin = procyanidin B3),
[6′,6]-all-trans-bi-(+)-catechin, procyanidin B1, procyanidin B2,
procyanidin B5, (+)-catechin-[4,8]-(+)-catechin-[4,8]-
(+)-catechin, (+)-catechin-[6′,8]-(+)-catechin-[4,8]-(+)-catechin;
triterpenoids: 2a,3b-dihydroxyurs-12 -en-28-oic acid b-D-
glucopyranosyl ester, 3-epi-pomolic acid 28-O-b-D-glucoside,
3b,19a-dihydroxyolean-12-en-28-oic acid b-D-glucopyranosyl
ester , 3b ,19a-dihydroxyurs-12-en-28-oic acid b-D-
glucopyranosyl ester, arjunetin, chinovic acid, kaji-ichogoside F1,
tormentic acid, tormentoside (Tomczyk and Latté, 2009; Melzig
and Böttger, 2020).
Posology (based on traditional uses). 1.5–2.0 g per 100 ml of
water, as an infusion, or 0.8–3.0 g per 100 ml of water, as a
decoction. The preparation should be used to rinse the mouthFrontiers in Pharmacology | www.frontiersin.org 18several times daily (EMA, 2010). It is preferable to use a
commercial preparation (e.g., tincture) with a defined
composition and an adequate dose.
Preclinical evidence. This herbal medicine has not been
experimentally proven for symptoms of respiratory disease.
However, a moderate antiviral effect against Herpes viridae has
been demonstrated for extracts of P. erecta and hydrolyzable and
condensed tannins isolated from this plant. In particular, the
antiviral activity against Herpes virus types I and II was reported,
as well as the cytotoxic activity against Influenza virus type A2
and Cowpox (May, 1978). An agrimoniin-rich ethanolic extract
of P. erecta inhibited the NF-kB and formation of IL-6, and PGE2
in TNF−a stimulated HaCaT cells (Wölfle et al., 2017). An
animal test system with mice supported the demonstrated
antiviral effects against the Vaccine virus together with an
induction of interferon synthesis (May, 1978; Lund and
Rimpler, 1985).
Clinical evidence. Potentilla erecta has not been trialed
clinically for respiratory disease. Overall, the clinical evidence
is Low.
Safety. Due to the limited studies in humans, animal models
are used as alternatives to evaluate the safety of P. erecta. Acute
toxicity of an aqueous extract of tormentil was assessed in
animals using a single oral dose of 2.5 and 6.8 g/kg. No
apparent toxic effect was observed. Potentilla erecta extracts
should be considered safe for acute toxicity when also applied
to humans (Shushunov et al., 2009).
Special warnings and precautions of use. Due to thrombolytic
activity (Melzig and Böttger, 2020), caution should be taken to
avoid interaction with thrombolytic drugs. Therefore, safety
is Medium.
Overall assessment. Potentilla erecta preparations reportedly
have relevant anti-viral effects, but the main uses are for buccal
sores and inflammation. It is not established that it has a specific
effect on the respiratory tract. The clinical evidence is Low, but
this herbal medicine is considered presenting Medium safety.
Primula veris L. - Primulaceae (Roots)
Indications in the context of respiratory conditions. Primula
veris is indicated for some symptoms of respiratory diseases,
namely cough (EMA, 2012b).
Chemical composition. Saponins (e.g., primulasaponin I,
primulasaponin II) (Müller et al., 2006); flavonoids (e.g.,
quercetin, luteolin, kaempferol, and isorhamnetin derivatives);
phenolic acids (e.g., chlorogenic acid) (Bączek et al., 2017).
Posology. 0.2–0.5 g in 150 ml of boiling water, as an infusion,
3 times daily (EMA, 2012b). It is preferable to use a commercial
preparation with a defined composition and an adequate dose.
Preclinical evidence. This herbal medicine has not been
experimentally proven for symptoms of respiratory diseases.
However, a P. veris dry extract presented potential anti-
inflammatory activity in vitro, reducing IFN-g, and inhibited
prostaglandin and leukotriene synthesis. Also, inhibited the
replication of human rhinovirus (HRV) and respiratory syncytial
virus (RSV) (Seifert et al., 2012). A hydroalcoholic extract of P. veris
presented anti-inflammatory activity in rats in the carrageenan-
induced paw edema test (Marchyshyn et al., 2017).September 2020 | Volume 11 | Article 581840
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for respiratory diseases. Overall, the clinical evidence is Low.
Safety. Cases of nausea, vomiting, gastric disturbances, and
allergies may occur in doses higher than recommended (EMA,
2012b; Ghédira and Goetz, 2017). Overall, safety is High.
Special warnings and precautions of use. Concerns were
raised over the concomitant use of P. veris and warfarin
(Řehulková, 2001).
Overall assessment. Although Primula veris is not clinically
proven to provide symptomatic relief offlu symptoms, it could be
useful in the relief of the respiratory symptoms through an anti-
inflammatory effect. The clinical evidence is Low, but this herbal
medicine is considered presenting Medium safety.
Salix alba L., Salix sp. – Salicaceae (Cortex)
Indications in the context of respiratory conditions. Salix alba is
indicated as antipyretic (BRASIL, 2011; EMA, 2017d); Other
indications are as anti-inflammatory, and in the treatment of the
flu and common cold (WHO, 2009).
Chemical composition. It is generally standardized to salicin.
However, other salicylates, polyphenols, and flavonoids may also
play important roles in therapeutic actions (Shara and Stohs,
2015). Some components: (+)-catechin, syringin, triandrin,
ampelopsin, ethyl-1-hydroxy-6-oxocyclohex-2-enecarboxylate
taxifolin, 3-O-methyltaxifolin, 7-O-methyltaxifolin-3-O-
glucoside; p-coumaric, benzoic, p-hydroxybenzoic, p-methoxy
benzoic, cinnamic, trans-p-methoxycinnamic, and cis-p-
methoxy cinnamic acids (Agnolet et al., 2012).
Posology (based on traditional uses). 3 g dry stem barks in
150 ml as a decoction, 2–3 times a day (BRASIL, 2011). 1–3 g of
the stem bark in 150 ml of boiling water three times daily
(EMA, 2017d).
Preclinical evidence. This herbal medicine has been
experimentally proven for fever. Its efficacy and safety have
been reported in several studies. Salix alba extract showed
significant analgesic as well as anti-inflammatory properties in
mice and showed more potency than the standard drug aspirin in
all the doses tested (Gyawali et al., 2013).
Clinical evidence. Salix alba preparations have been trialed
clinically for fever and inflammation. A randomized study with
210 patients was conducted to evaluate the effectiveness of Salix
bark extract for the treatment of low back pain. Patients received
bark extract orally with 120 mg or 240 mg of salicin or placebo in
4-week. In the last week of treatment, 39% of patients were pain-
free for the high dose, 21% for the low dose, and 6% for the
placebo (Chrubasik et al., 2000). Another randomized placebo-
controlled, double-blind study was conducted involving 78
patients with osteoarthritis. Patients received placebo or willow
bark extract containing 240 mg salicin per day for 2 weeks. In the
willow bark extract group, the WOMAC pain score was reduced
by 14% after 2 weeks, compared with an increase of 2% in the
placebo group. Therefore, Salix extract was well tolerated, with
no adverse effects reported (Schmid et al., 2001). Patients (436)
with osteoarthritis and rheumatic pain or back pain or both
conditions received by 6-month mono or combination therapy
with aqueous Salix extract, opioids, and NSAIDs. The results
showed that in conjunction with the use of the Salix extract, theFrontiers in Pharmacology | www.frontiersin.org 19pain scores were between 33% and 44% of baseline. Drug
interactions were not reported (Uehleke et al., 2013). Overall,
the level of evidence is High for pain.
Safety. Oral administration of a Salix alba ethanol extract
when administered to female rabbits and rats did not disrupt the
estrous cycle, or inhibit ovulation or fertility and was not
teratogenic or embryotoxic at a dose of 1.6 ml/kg (WHO,
2009). Salix alba ethanol extract (1.6 ml/kg, intragastric
administration, in rats for 13 weeks) had no effect on kidney
function, hematological parameters, cholesterol levels, or liver
function. The results of the histological evaluation showed no
pathological changes in the heart, brain, lungs, kidneys, bone,
liver, mammary tissue, reproductive organs, intestines, or
stomach (WHO, 2009). In mice (both sexes), S. alba ethanol
extract presented a median lethal dose range of 28.0–42.0 ml/kg
(WHO, 2009). In children can cause a risk of Reye’s syndrome,
then it is not recommended (El-Radhi, 2018). Also, the use is not
recommended in patients with hypersensitivity to other
nonsteroidal anti-inflammatory drugs. People with asthma
(sensibility to salicylates) due to severe reactions (acute
bronchospasms) should avoid the use (WHO, 2009).
Specific warnings and precautions of use. In the case of treatment
with anticoagulants, antacids, corticosteroids, or NSAIDs, the use of
salix should be avoided (EMA, 2017d). Do not use it in people with
gastrointestinal disorders and sensitivity to salicylic acid (BRASIL,
2011).Overall, due to the antiplatelet effect, in the context ofCOVID-
19, the safety should be considered Medium.
Overall assessment. Salix alba profile and chemistry fit as an
anti-inflammatory and antipyretic therapy in the context of upper
respiratory affections. Therefore, this herbal medicine may be
useful in the symptomatic relief of respiratory symptoms through
exerting an anti-inflammatory and antipyretic effect. The clinical
evidence is High. Due to its antiplatelet effects, this herbal medicine
is considered presenting Medium safety in the COVID-19 context.
Sambucus nigra L. – Adoxaceae (Dried Flowers)
Indications in the context of respiratory conditions. Sambucus
nigra is indicated for fever and inflammation of the respiratory
tract (WHO, 2002; BRASIL, 2011). Other indications are to
relieve cold and flu symptoms, to alleviate headaches, and as
expectorant (EMA, 2018e; Torabian et al., 2019).
Chemical composition. Flavonoids, such as kaempferol,
astragalin, quercetin, rutin, isoquercitrin, hyperoside;
triterpenes (a- and b-amyrin, ursolic acid, oleanolic acid);
sterols (b-sitosterol, campesterol, stigmasterol); phenolic acids
and their corresponding glycosides (chlorogenic, ferulic, caffeic
and p-coumaric acids); and essential oil (Sidor and Gramza-
Michałowska, 2015).
Posology (based on traditional uses). 3–5 g of dried flowers in
25 ml as an infusion three times daily. Store in a well-closed
container, protected from light (Bradley, 1992). 2–5 g dried
flowers in 150 ml as an infusion, 2–3 times a day; 3–6 g dried
flowers in 150 ml as a decoction, 2–3 times a day (EMA, 2018e).
Preclinical evidence. This herbal medicine has been
experimentally proven for fever. The active constituents inhibit
the biosynthesis of the inflammatory cytokines IL-1a, IL-1b, and
tumor necrosis factor-a in human peripheral mononuclear cellsSeptember 2020 | Volume 11 | Article 581840
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vitro and in vivo experiments have shown the antiviral effects of
extracts from elderberries, against Influenza virus (Serkedjieva
et al., 1990; Zakay-Rones et al., 1995; Krawitz et al., 2011;
Kinoshita et al., 2012; Porter and Bode, 2017).
Clinical evidence. Sambucus nigra preparations have been
trialed clinically for common cold and flu. Two randomized
studies with a standardized extract, involving patients presenting
influenza symptoms and positive reaction for Influenza virus
type A or B, showed the reduction of the symptoms after the
second day of treatment, without significant adverse effects
(Zakay-Rones et al., 1995; Zakay-Rones et al., 2004). In
another randomized study with air travelers, the group using S.
nigra presented less cold episodes than the placebo group
(Tiralongo et al., 2016). A meta-analysis of randomized clinical
studies led to the conclusion that S. nigra supplementation
reduces upper respiratory symptoms of common cold and
influenza (Hawkins et al., 2019). Overall, the level of evidence
is High for cold and flu.
Safety. No information available on general precautions or
concerning drug interactions; non-teratogenic effects in
pregnancy or pediatric use (EMA, 2017c). Overall, safety is High.
Specific warnings and precautions of use. None.
Overall assessment. Sambucus nigra is traditionally used as
cold therapy in the context of upper respiratory conditions and
could be useful in the relief of respiratory symptoms through
exerting anti-inflammatory and antipyretic effects. The clinical
evidence is High, and this herbal medicine is considered
presenting High safety.
Scutellaria baicalensis Georgi – Lamiaceae (Roots)
Indications in the context of respiratory conditions. Scutellaria
baicalensis is indicated for fever (WHO, 2007). Other related
indications are as antiviral and to relieve bronchitis symptoms
(WHO, 2007; Zhao et al., 2019).
Chemical composition. Flavonoids such as wagonin,
baicalcin, and baicalin are the main components (Zobel et al.,
1991; Kovács et al., 2004; Reichling and Galati, 2004; Abdollahi
Fard, 2012); essential oil (Fukuhara et al., 1987); terpenoids and
steroids (e.g., b-caryophyllene, scutebaicalin, b-sitosterol)
(Hussein et al., 1996).
Posology (based on traditional uses). 1-2 g of dried roots in
150 ml of boiling water, as an infusion, three times daily (Barnes
et al., 2012). 3-9 g of dried roots as infusion or decoction
(WHO, 2007).
Preclinical evidence. Scutellaria baicalensis has been not
experimentally proven for symptoms of respiratory disease.
Other related experimental effects include anti-inflammatory.
The anti-inflammatory activity was evaluated by in vitro and in
vivo experiments. Extracts inhibited the production of NO,
interleukin (IL)-3, IL-6, IL-10, IL-12p40, IL-17, interferon-
inducible protein (IP)-10, keratinocyte-derived chemokine, and
vascular endothelial growth factor (VEGF) in LPS-induced RAW
264.7 cells (Yoon et al., 2009). Moreover, the aqueous extract of
S. baicalensis suppressed LP-induced COX-2 protein expression
in vitro, as well as presented analgesic and anti-inflammatory
activities in vivo (Lee et al., 2007).Frontiers in Pharmacology | www.frontiersin.org 20Clinical evidence. This herbal medicine has been not trialed
clinically for the following symptom: bronchitis, cough, fever, flu,
cold. Overall, the clinical evidence is Low.
Safety. Some stomach discomfort and diarrhea were observed
in patients taking preparation of S. baicalensis (WHO, 2007). In a
randomized, double-blind trial, involving 72 healthy subjects,
baicalein (100–2,800 mg) was safe and did not present severe
adverse effects (Li et al., 2014). There are reports of baicalein
being able to stimulate the ACE2 activity, though (ANSES, 2020).
Therefore, safety is Medium.
Special warnings and precautions of use. Scutellaria
baicalensis should not be used in people with spleen and
stomach deficiency (Dinehart and Henry, 2005).
Overall assessment. Scutellaria baicalensis may be useful in
the relief of respiratory symptoms through the anti-
inflammatory activity. The clinical evidence is Low. This herbal
medicine is considered presenting Medium safety.
Silybum marianum L. Gaertn. - Asteraceae (Fruits)
Indications in the context of respiratory conditions. Silybum
marianum is indicated for symptoms of respiratory disease,
namely fever, and catarrh (WHO, 2002).
Chemical composition. Flavonolignans such as silymarin,
silybin, isosilybin and taxifolin (1.5–3.0%) are the main
components reported for S. marianum (Wynn, 1999; Porwal
et al., 2019); flavonoids (quercetin derivatives); phenolic acids
(chlorogenic, caffeic and ferulic acids) (Lucini et al., 2016;
Valková et al., 2020).
Posology (based on traditional uses). It is preferable to use a
commercial preparation with a defined composition and an
adequate dose.
Preclinical evidence. Silybum marianum has not been
experimentally proven for symptoms of respiratory disease.
Silybin, the main flavonolignan from the seed of S. marianum,
has demonstrated an anti-inflammatory activity by inhibiting the
spontaneous and LPS-stimulated NF-kB activation as well as the
production of inflammatory cytokines (Corchete, 2008; Giorgi
et al., 2012).
Clinical evidence. Silybum marianum has not been trialed
clinically for respiratory diseases. Overall, the clinical evidence
is Low.
Safety. At high doses, mild laxative effect, as well as mild
allergic reactions, have been reported (Blumenthal, 2003; Lucini
et al., 2016), besides dry mouth, nausea, upset stomach, gastric
irritation or headache (EMA, 2016d). A preparation containing
7%–8% silymarin appeared to be safe for up to 41 months of use
(Corchete, 2008). Overall, safety is High.
Specific warnings and precautions of use. None.
Overall assessment. Although S. marianum is not clinically
proven to provide symptomatic relief offlu symptoms, it could be
useful in the relief of respiratory symptoms by exerting a
systemic anti-inflammatory effect. The clinical evidence is Low.
This herbal medicine is considered presenting High safety.
Thymus vulgaris L. - Lamiaceae (Aerial Parts, Leaves)
Indications in the context of respiratory conditions. Thymus
vulgaris is indicated for productive cough associated with cold,September 2020 | Volume 11 | Article 581840
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EMA, 2013c).
Chemical composition. Essential oil (thymol as the major
component); phenolic acids (rosmarinic, ferulic, syringic,
coumaric acids), tannins (gallic and protocatechuic acids),
flavonoids (luteolin, apigenin, cirsilenol, thymonin, and
derivatives, besides others) (Van Den Broucke and Lemli,
1983; Kuete, 2017; Salehi et al., 2019a).
Posology (based on traditional uses). 1–2 g of dried leaves in
150 ml, as an infusion, 3–4 times daily (EMA, 2013c).
Preclinical evidence. Thymus vulgaris has not been
experimentally proven for symptoms of respiratory disease.
However, the myorelaxant effect of ethanolic extract and
flavonoids from T. vulgaris was evaluated in isolated guinea-
pig trachea contracted by acetylcholine. The extract promoted
relaxation, similar to DL-isoprenaline (Van Den Broucke and
Lemli, 1981). The most active flavonoids were cirsilineol,
thymonin, and 8-methylcirsilineol, acting as non-competitive
and non-specific Ca2+ antagonists (Van Den Broucke and Lemli,
1983). An evaluation of T. vulgaris essential oil in rats, through
classic methods, showed that the essential oil presents anti-
inflammatory activity. Additional experiments showed that
carvacrol plays an important role in the activity, with anti-
edematogenic and anti-chemotactic action. The inhibition of
chemotaxis was also proven by in vitro experiments. On the
other hand, thymol promoted the release of histamine acting as
an irritative agent (Fachini-Queiroz et al., 2012). The
hydroethanolic extract of T. vulgaris also presents myorelaxant
activity ex vivo (Meister et al., 1999; Boskabady et al., 2006b). An
aqueous extract of T. vulgaris presented in vitro activity against
Herpes simplex virus type 1 (HSV-1), type 2 (HSV-2), and HSV-1
acyclovir-resistant (Nolkemper et al., 2006).
Clinical evidence. This herbal medicine has been not trialed
clinically, as monodrug, for respiratory disease. Clinical
evaluation of thyme has been carried out as an association
with another herbal drug, such as P. vulgaris. Overall, the
clinical evidence is Low.
Safety. In traditional doses, there is no report about the
toxicity of T. vulgaris. However, high doses (around 10 g) are
considered unsafe due to thymol (Basch et al., 2004). Overall,
safety is High.
Specific warnings and precautions of use. The use is
contraindicated for hypersensitivity to the active substance.
Children under 30 months of age should not use this plant due
to thymol containing preparations, which can induce
laryngospasm (WHO, 1999; EMA, 2013c).
Overall assessment. Although T. vulgaris is not clinically
proven to provide symptomatic relief of flu symptoms, it may
be useful in the relief of respiratory symptoms through
spasmolytic and anti-inflammatory effects. The clinical
evidence is Low. This herbal medicine is considered presenting
High safety.
Tilia cordata Mill. – Malvaceae (Flowers)
Indications in the context of respiratory conditions. Tilia cordata
is indicated for symptoms of the common cold (CHILE, 2010;
EMA, 2012c).Frontiers in Pharmacology | www.frontiersin.org 21Chemical composition. Essential oil (main components are
alkanes, such as 6,10,14-trimethyl-2-pentadecanone and
tricosane, besides linalool, E-anethole) (Fitsiou et al., 2007;
Kowalski et al., 2017); flavonoids (e.g., quercetin, kaempferol,
and derivatives; tiliroside), anthocyanins (Negri et al., 2013;
Fawzy et al., 2018).
Posology. 1.5 g in 150 ml of boiling water, as an infusion, 2–4
times daily (CHILE, 2010; EMA, 2012c)
Preclinical evidence. This herbal medicine has not been
experimentally proven for the symptoms of respiratory disease.
However, procyanidins present in small flowers were evaluated
about an inflammatory response in human neutrophils in the
concentration ranging from 5 to 20 mM. All compounds were
able to decrease ROS production from f-MLP-stimulated
neutrophils. Most compounds were able to inhibit LPS-induced
IL-8 release. Some trimeric and tetrameric derivativeswere also able
to decrease the production of MIP-1b. A hydromethanolic extract
presented anti-inflammatory and antinociceptive activities in rats,
in a similar way than indomethacin and acetylsalicylic acid,
respectively (Fawzy et al., 2018).
Clinical evidence. This herbal medicine has been not trialed
clinically for respiratory diseases. Overall, the level of evidence
is Low.
Safety. Overall safety is High, as there are not reports to infer that
the preparations from the plant may interfere with the disease.
Specific warnings and precautions of use. Flavonoids present
in T. cordata exert an anxiolytic effect and can, potentially,
interact with serotonergic drugs (Noguerón-Merino et al., 2015).
Overall assessment. Tilia cordata is not clinically proven to
provide symptomatic relief of flu symptoms. However, this herbal
medicine may be useful in the relief of respiratory symptoms
through an anti-inflammatory effect. The clinical evidence is Low.
This herbal medicine is considered presenting High safety.
Zingiber officinale Roscoe - Zingiberaceae (Rhizome)
Indications in the context of respiratory conditions. Zingiber
officinale is indicated for common cold and cough (COLOMBIA,
2008). Its use as anti-asthma (WHO, 1999) and expectorant
(BRASIL, 2011) have also been reported.
Chemical composition. Zingerone, shogaols, gingerols,
paradols, wikstromol, and carinol (Idris et al., 2019). Total
phenolic of 1.02 ± 0.03 mg gallic acid equivalent/L of infusion
(Mesquita et al., 2018).
Posology (based on traditional uses). 1 g of dried rhizoma in
150 ml, 3–4 times daily (BRASIL, 2011; EMA, 2011b).
Preclinical evidence. This herbal medicine has been
experimentally proven for fever (Ueki et al., 2008; Akbar, 2020). It
is described in several preclinical studies report its anti-
inflammatory, antipyretic and analgesic properties (Mascolo
et al., 1989; El-Abhar et al., 2008; Sepahvand et al., 2010; Ahmed
et al., 2011; Darvishzadeh-Mahani et al., 2012; Hsiang et al., 2013;
Rashidian et al., 2014). The anti-inflammatory effect of ginger is
well established as in vivo as in vitro models (Thomson et al.,
2002; Ali et al., 2008). 6-Shogaol interferes with the inflammatory
cascade, inhibitsCOX, and theprostaglandin release (Rehmanetal.,
2011). Moreover, 6-gingerol and 6-shogaol present anti-platelet
aggregation activity in vitro (Liao et al., 2012).September 2020 | Volume 11 | Article 581840
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clinically for respiratory diseases. In a randomized study, 32
patients with acute respiratory distress syndrome (ARDS)
received an enteral diet enriched with ginger or placebo, through
a nasogastric tube, during 21 days. On day 5, the patients that
received gingerpresented lower serumlevelsof IL-1, IL6, andTNFa,
while the level of RBC glutathione presented higher in comparison
with the placebo group. Moreover, a significant improvement in
oxygenation was observed in the ginger group. The same results
were observed on day 10. The authors described that there was a
significant difference in the duration of mechanical ventilation and
in the time expended in the intensive care unit. However,
barotrauma, organ failure, and mortality between ginger and
placebo groups were similar (Vahdat Shariatpanahi et al., 2013).
Overall, the level of clinical evidence is Medium.
Safety. Although regulatory authorities recommend avoiding
the use in pregnancy and lactation (EMA, 2011b), ginger use
during pregnancy was reported as safe in Canadian, Australian
and Norwegian women (Portnoi et al., 2003; Willetts et al., 2003;
Westfall, 2004; Heitmann et al., 2013). Clinical studies found
ginger as effective and safe to prevent pregnancy-associated
nausea and vomiting (Borrelli et al., 2005; Ding et al., 2013). In
human liver microsomes, the hydroethanolic extract inhibited
CYP2C19 and CYP2D6 (Kim et al., 2012; Gorman et al., 2013).
Specific warnings and precautions of use. Stomach upset,
eructation, dyspepsia, and nausea have been reported (EMA,
2011b). High doses (12–14 g) of ginger may increase the effects of
anticoagulant therapy (Thomson et al., 2002; BRASIL, 2011;
BRASIL, 2016). Studies showed the effect of ginger on
cytochrome P450 enzyme-mediated drug metabolism, which
can cause interference on the outcome of the treatment of
some conventional drugs. Ginger stimulated levels of CYP450
and cytochrome b5 in rats (Sambaiah and Srinivasan, 1989). The
use is contraindicated for people with gallstones, gastric
irritation, and high blood pressure (BRASIL, 2011). Overall,
safety is Medium due to the potential antiplatelet activity.
Overall assessment. Zingiber officinale profile and chemistry
fit as an anti-inflammatory therapy in the context of upper
respiratory affections. Therefore, this herbal medicine may be
useful in the relief of respiratory symptoms through exerting an
anti-inflammatory effect. The clinical evidence is Medium. This
herbal medicine is considered presenting Medium safety.
Herbal Remedies Used to Relieve
Symptoms Related to Respiratory
Conditions Not Listed By International
Monographs
Some species, although without the support of official
documents, have been widely used to relieve common cold
symptoms, usually as homemade preparations. Some of them
are analyzed here, in the COVID-19 context.
Citrus limon (L.) Burm. f. – Rutaceae (Fruit)
Indications in the context of respiratory conditions. Citrus limon
has been used to relieve cough, and as expectorant in bronchitis
(Papp et al., 2011; Klimek-Szczykutowicz et al., 2020); and asFrontiers in Pharmacology | www.frontiersin.org 22anti-inflammatory (Parhiz et al., 2015), sore throat (Balogun and
Ashafa, 2019).
Chemical composition. Essential oil (limonene and a-
terpineol as major components) (Mahalwal and Ali, 2003);
flavonoids (e.g., hesperidin, hesperetin, naringenin) (Abad-
Garcıá et al., 2012; Parhiz et al., 2015); phenolic acids (e.g., p-
cumaric, ferulic, quinic acids and derivatives) (Abad-Garcıá
et al., 2012), coumarins and furanocoumarins; vitamin C
(Klimek-Szczykutowicz et al., 2020).
Posology. Slices of whole fruit or fresh pericarp, as a
decoction, 2–3 times daily; expressed juice (Panizza et al., 2012).
Preclinical evidence. This herbal medicine has not been
experimentally proven for respiratory disease.
Clinical evidence. This species has not been trialed clinically
for respiratory disease. Overall the clinical evidence is Low.
Safety. Citrus limon is an edible fruit, therefore, considered safe,
although there may be a risk of minor burns on the skin if in contact
with sun exposure, due to the presence of furanocoumarins
(Palazzolo et al., 2013). Overall safety is High.
Specific warnings and precautions of use. Citrus flavonoids
can exert severe interaction with drugs metabolized by inhibition
of CYP3A4, CYP2C9 (Bailey et al., 1998; Mallhi et al., 2015).
Citrus limon presents anti-platelet activity. Therefore, the
concomitant use with anti-platelet drugs should be avoided.
Overall assessment. Citrus limon can be useful in the relief of
respiratory symptoms, especially coughand sore throat.The clinical
evidence isLow.Due to its antiplatelet effects, thisherbalmedicine is
considered presenting Medium safety in the COVID-19 context.
Culcitium canescens H&B. – Asteraceae (Leaves and
Roots)
Indications in the context of respiratory conditions. In Peru and
adjoining countries, Culcitium canescens is used to relieve cough
and fever (Okuyama et al., 1994). Another related indication
includes asthma (D’Agostino et al., 1995; Ramirez et al., 2020)
Chemical composition. Furanoeremophilanes (e.g., cacalonol,
cacalohatine, dehydrocacalohastine) (Abdo et al., 1992;
Okuyama et al., 1994); phenolic compounds (e.g., kaempferol
and derivatives, quercetin and derivatives, caffeic acid)
(D’Agostino et al., 1995); terpenes and steroids (spatulenol,
lupeol, damaradienone) (Ramirez et al., 2020).
Posology (based on traditional uses). 1–2 g of leaves in 150ml, as
an infusion, up to three times daily (Ramirez et al., 2020).
Preclinical evidence. Culcitium canescens has not been
experimentally proven for respiratory disease.
Clinical evidence. This species has not been trialed clinically
for respiratory disease. Overall the clinical evidence is Low.
Safety. Little or anything is known about the toxicity of this
plant (Ramirez et al., 2020).
Specific warnings and precautions of use. None.
Overall assessment. Although Culcitium canescens profile and
chemistry fit as an anti-inflammatory therapy in the context of
upper respiratory affections, and preparations are traditionally
used, the lack of knowledge about this species does not allow a
clear recommendation for the relief of early symptoms of
COVID-19. The clinical evidence is Low.September 2020 | Volume 11 | Article 581840
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Indications in the context of respiratory conditions. Laurus
nobilis is used to treat respiratory infections (Chevallier, 1996;
Ross, 2001).
Chemical composition. Berries: essential oil (b-ocimene and
1,8-cineole as the main components); sterols (e.g., b-sitosterol);
flavonoids (cyanidin 3-O-glucoside and cyanidin 3-O-
rutinoside, as the major anthocyanins) (Kilic et al., 2004; Beis
and Dunford, 2006; Abu-Dahab et al., 2014). Leaves: essential oil
(1,8-cineole and a-terpinyl acetate as the major compounds)
(Fidan et al., 2019). Further phytochemical investigations of
laurel leaves led to the isolation of sesquiterpene lactones,
alkaloids, glycosylated flavonoids, and monoterpene and
germacrane alcohols (Dall’Acqua et al., 2009).
Posology (based on traditional uses). The only dosage
information on L. nobilis is given by the American
Pharmaceutical Association: 1–2 tablespoons leaf/cup water
and 3 times/day or 1–2 drops of essential oil added to honey,
or tea (Duke et al., 2002).
Preclinical evidence. This species has not been experimentally
proven for respiratory disease. The closest experiment is an in
vitro study examining SARS-CoV and the effect of several
essential oils. The authors reported that a distilled oil extracted
from Laurus nobilis berries was an effective virucidal against
SARS-CoV. This essential oil also contained eremanthin and
dehydrocostus lactone as minor constituents at 3.65% and 7.57%,
respectively. These compounds are somewhat unusual in
essential oils, but at least one in vitro study found that
dehydrocostus lactone had activity against the hepatitis B virus,
an enveloped DNA virus (Loizzo et al., 2008). The essential oil of
L. nobilis has also been evaluated for its antinociceptive and anti-
inflammatory activities in mice and rats. The essential oil
exhibited a significant analgesic effect in tail-flick and formalin
tests, a dose-dependent anti-inflammatory effect in formalin-
induced edema, and a moderate sedative effect at the anti-
inflammatory doses (Sayyah et al., 2003).
Clinical evidence. This species has not been trialed clinically
for respiratory disease. Overall, the clinical evidence is Low.
Safety. There is not enough reliable information about the safety
of taking L. nobilis leaves and berries. As L. nobilis has been used as
food since ancient times, overall, it can be considered safe in the
recommended doses. Therefore, safety is High.
Specific warnings and precautions of use. None.
Overall assessment. Laurus nobilis profile and chemistry fit as an
anti-inflammatory therapy in the context of upper respiratory
affections. Therefore, this herbal medicine could be useful in the
relief of respiratory symptoms through exerting anti-viral and anti-
inflammatory effects on the respiratory tract. The clinical evidence is
Low. This herbal medicine is considered presenting High safety.
Lippia graveolens Kunth. – Verbenaceae (Leaves,
Aerial Parts)
Indications in the context of respiratory conditions. Lippia
graveolens is used to treat symptoms of respiratory diseases,
and as anti-inflammatory (Rastrelli et al., 1998).
Chemical composition. Iridoid and secoiridoid glucosides and
ester derivatives (Rastrelli et al., 1998); essential oil (thymol,Frontiers in Pharmacology | www.frontiersin.org 23limonene, carvacrol, as the major components) (Compadre et al.,
1987; Uribe-Hernández et al., 1992); lipids (esterols) and
flavonoids (e.g., pinocembrin, luteolin, apigenin, quercetin and
derivatives) (Lin et al., 2007; Arias et al., 2020); rosmarinic acid
(Compadre et al., 1987).
Posology (based on traditional uses). 1–2 g of dried leaves or
stem in 150 ml of water (Dominguez et al., 1989).
Preclinical evidence. This species has not been experimentally
proven for respiratory disease. Flavonoid and terpenoid fractions
from Lippia genus have demonstrated a significant inhibitory
effect on ROS and NO production and mitochondrial activity in
LPS-induced inflammation in RAW 264.7 macrophage cells.
Additionally, these fractions exhibited non-selective inhibitions
against the activity of the cyclooxygenases COX-1 and COX-2
(Leyva-López et al., 2016).
Clinical evidence. This species has not been trialed clinically
for respiratory disease. Overall, the clinical evidence is Low.
Safety. In the United States, the regulatory status “generally
recognized as safe” has been accorded to Mexican oregano
(GRAS 2827). Therefore, safety is High.
Specific warnings and precautions of use. None.
Overall assessment. Lippia graveolens profile and chemistry fit
as an anti-inflammatory therapy in the context of upper
respiratory affections. Therefore, this herbal medicine could be
useful in the relief of respiratory symptoms through exerting an
anti-inflammatory effect. The clinical evidence is Low. This
herbal medicine is considered presenting High safety.
Nigella sativa L. - Ranunculaceae (Seeds)
Indications in the context of respiratory conditions. Black seeds
are globally known as a spice and as such as a food item. In
Arabic medicine, they have very high status as an herbal
medicine used for a wide range of diseases. In the context of
COVID-19, the relevant uses are for asthma and in the more
general management of inflammatory conditions. In many
Arabic countries, black seed is used for asthma and cough,
among many other uses, especially for gastrointestinal diseases
(like abdominal pain, stomach ache, colic), rheumatism, skin
diseases (Lebling and Pepperdine, 2006).
Chemical composition. Relevant secondary metabolites in the
seed include large quantities of fixed oil (30%–45%; especially
linoleic and oleic acids), various triterpenoids, including
saponins; essential oil, with a relatively high concentration of
thymoquinone (2-isopropyl-5-methyl-1,4-benzoquinone),
which is also a key therapeutically relevant of the fixed oil,
where it can be found in concentrations varying from 3.5 to 8.7
mg/g of fixed oil (Lutterodt et al., 2010). Thymoquinone is not
found in relevant concentrations in aqueous preparations.
Posology. Capsules containing fatty oil with a defined amount
of thymoquinone are likely to be the best option. Herbal teas and
other hydrophilic preparations seem less likely to have benefits,
and potentially the essential oil may offer some relief.
Preclinical evidence. In rats, a chemically not well
characterized 50% ethanol extract (1:4) of chopped N. sativa
seeds (extraction at room temperature for 72 h) showed
ameliorating effects on lung inflammation and oxidative stress
induced by lipopolysaccharide. In general, many study focus onSeptember 2020 | Volume 11 | Article 581840
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mostly these are of highly inadequate scientific quality.
Clinical evidence. Some small studies demonstrate clinical
benefits in asthma patients. In a randomized, double-blind,
placebo-controlled trial supplementation of standard therapy with
soft gel capsules of cold-pressed N. sativa oil (0.7% thymoquinone)
improved asthma control with a trend in pulmonary function
improvement. Two of the five subscores (impact of asthma on
work, school, or at home and shortness of breath and the overall
score) showed a significant improvement. The other three were not
significantly improved.At the sametime, a remarkablenormalization
of blood eosinophilia count was observed (Koshak et al., 2017). The
release of IL-2, IL-6, and PGE2 in T-lymphocytes, as well as IL-6 and
PGE2 inmonocytes,were suppressed.Overall, the clinical evidence is
Medium for asthma.
Safety. As a commonly used food item, it can be considered to
be intrinsically safe. However, this does not apply to the
lipophilic extracts discussed above. Here further evidence is
essential. Insufficient evidence is available in the context of
uses as an adjuvant medication (Nguyen et al., 2019). Overall,
safety is High.
Specific warnings and precautions of use. Again, there is no
evidence for specific therapeutic benefits, and it is important to
communicate this to potential users. There is insufficient
evidence for use during pregnancy and while breastfeeding.
Overall assessment. Black seed may be useful in the relief of
respiratory symptoms mainly associated with the severe cough
experienced, and it may reduce inflammatory parameters. The
clinical evidence is very limited, focusing on asthma. A particular
concern, in this case, are themanywell-intendedbut very low-quality
studies and the broad range of claims they try to support,making any
assessmentproblematic.Theclinical evidence isMedium.Thisherbal
medicine is considered presenting High safety.
Plectranthus amboinicus Lour. – Lamiaceae (Leaves)
Indications in the context of respiratory conditions. Plectranthus
amboinicus has been used in asthma and to relieve cold,
headache, and fever (Menéndez Castillo and Pavón González,
1999; Duke et al., 2002).
Chemical composition. Essential oil (thymol and carvacrol as
the major components) (Pino et al., 1990; Arumugam et al.,
2016); phenolic compounds (e.g., rosmarinic, caffeic, gallic and
p-coumaric acids; quercetin derivatives; luteolin) (Brieskorn and
Riedel, 1977b; Arumugam et al., 2016), terpenoids and steroids
(e.g., b-sitosterol, a-amyrin, stigmasterol) (Brieskorn and Riedel,
1977a; Risch et al., 2012).
Posology (based on traditional uses). 3–5 g of fresh leaves in
150 ml, as an infusion, up to three times daily (Albornoz, 1993;
Matos et al., 2001).
Preclinical evidence. This herbal medicine has not been
experimentally proven for respiratory disease. Aqueous and
ethanolic extracts of P. amboinicus present in vitro anti-
inflammatory activity (Devi and Periyanayagam, 2009;
Ravikumar et al., 2009; Janakiraman and Somasundaram, 2014).
The active constituents of P. amboinicus present inhibitory effects
on pro-inflammatory cytokines TNF-a, IL-6, and IL-1b
(Yashaswini and Vasundhara, 2011).Frontiers in Pharmacology | www.frontiersin.org 24Clinical evidence. This species has not been trialed clinically
for respiratory disease. Overall, the clinical evidence is Low.
Safety. No toxicity reported at the indicated dose (Albornoz,
1993; Matos et al., 2001). Overall, safety is High.
Specific warnings and precautions of use. The use is
contraindicated for hypersensitivity to the active substance.
Children, under 30 months of age, should not use this plant due
to thymol containing preparations, can induce laryngospasm (see
Thymus vulgaris).
Overall assessment. Plectranthus amboinicus profile and
chemistry fit as an anti-inflammatory therapy in the context of
upper respiratory affections and could be useful in the relief of
respiratory disease through exerting an anti-inflammatory effect
on the respiratory tract and in the treatment of fever. The clinical
evidence is Low, but this herbal medicine is considered
presenting High safety.
Discussion
General Discussion About the Position of International
Health Organizations, National Authorities, and
Professional Bodies on the Use of Herbal Medicines
Within the Context of COVID-19 Disease
The use of herbal medicines/food supplements to prevent, treat,
mitigate, diagnose, or cure coronavirus disease 2019 has not been
consistently addressed at a global level. China has been actively
exploring how to integrate traditional Chinese medicine (TCM)
into western therapy since the SARS outbreak in 2003. Based on
clinical results, the General Office of the National Health, and the
Office of the State Administration of Traditional ChineseMedicine
encouraged the integration of herbal TCM and Western medicine
in the treatment of respiratory complications in Coronavirus
infections with different prescriptions recommended in different
stages of disease (Leung, 2007). After SARS-CoV-2 disease
outbreak, a number of clinical trials with Traditional Herbal
Medicines (THM) have been added to the body of evidence with
some favorable findings when compared to standard antiviral
therapy (Langeder et al., 2020; Li et al., 2020; Luo et al., 2020;
Rastogi et al., 2020).
Therefore, it is not surprising that thousands of TCM
practitioners across China have been working along with
regular medical doctors to control the COVID-19 disease. The
clinical data generated from tens of thousands of confirmed cases
are being subjected to meta-analyses to ascertain their actual
effectiveness (Li et al., 2020). In the meantime, the Diagnosis and
Treatment Protocol of COVID-19 by the National Health
Commission has already advised to integrate TCM in the
treatment of COVID-19 patients to effectively relieve
symptoms such as fever, cough, sore throat, myalgia, and
fatigue, shorten the course of the disease, reduce the
probability of life-threatening complications (Xu et al., 2020).
In India, the Ayurveda Practitioners are following suit by
working on setting clear protocols with a rationale consistent with
their millenary system. The first line of defense recommended to
early-stage patients consists of the following herbal medicines:
Tinospora cordifolia (Willd.) Myers (Menispermaceae), Zingiber
officinale Roscoe (Zingiberaceae), Curcuma longa L.
(Zingiberaceae), Ocimum sanctum L. (Lamiaceae), GlycyrrhizaSeptember 2020 | Volume 11 | Article 581840
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(Acanthaceae), Andrographis paniculata (Burm.f.) (Acanthaceae),
Swertia chirata Buch.-Ham. ex Wall. (Gentianaceae), Moringa
oleifera Lam (Moringaceae), Triphala [a mixture of the dried
fruits of Emblica officinalis Gaertn. (Phyllanthaceae), Terminalia
bellirica (Gaertn.) Roxb. (Combretaceae), and Terminalia chebula
Retz.(Combretaceae)] and Trikatu [a complementary formula to
Triphala, including Piper nigrum L. (Piperaceae), Piper longum L.
(Piperaceae), andZ.officinale Roscoe] (Rastogi et al., 2020). Clinical
settings and regulations of research on COVID-19 through
Ayurveda, Unani, Siddha, and Homeopathy systems have already
been published by the Indian Ministry of Ayush (INDIA, 2020).
However, in Western medicine, we are witnessing quite the
opposite. Not only integration of herbal medicine is “out of the
question” from an emergency clinical point of view, but authorities
are also reluctant - if not discouraging - the self-prescription of any
products other than paracetamol in early stages of the disease. The
media trying to get answers about the benefits of herbal medicines
turn tomedical expertswhousually cautionagainst theuse ofherbal
medicines in order to avoid any liabilities. Oftentimes, dismissing
the potential of herbal medicines to relieve early COVID-19
symptoms is just an uncritical and legalist approach. An
international initiative from Brazilian Academic Consortium for
Integrative Health - CABSIn, TCIM Americas Network, and the
Latin-American and Caribbean Center on Health Sciences
Information (BIREME/PAHO/WHO) is systematizing the
available evidence about Traditional, Complementary and
Integrative Medicine (including herbal medicines) potentially
useful in the COVID-19 pandemic (Portella et al., 2020).
Traditional herbal medicines are poorly or not regulated as
licensed/registered medicines in quite a few countries, including
the USA, and therefore are considered “food,” precluding any
high-level discussion on their potential contributions to human
health. Consequently, the U.S. Food and Drug Administration
(FDA) considers fraudulent to sell any herbal products with
attached claims and has sent warning letters to companies
offering herbal products such as teas, essential oils, and
tinctures claiming to prevent, treat or cure the symptoms of
COVID-19. It is also encouraging the public to report the
unlawful sales of medicinal products on the Internet (FDA,
2020). The North American public is receiving advice on the
use of herbal products from dedicated academic groups. One of
them is the Andrew Weil Center for Integrative Medicine which
recommends polyphenol-rich plants (chamomille, Chinese
skullcap, licorice, onions, apples, tomatoes, oranges, nuts,
berries, parsley, celery, turmeric root, and green tea) to reduce
the risk of infection (Alschuler et al., 2020), but no detailed
assessment is available.
In Europe, Traditional Herbal Medicine Products (THMP)
are regulated by the EMA as OTC medicinal products for the
relief of mild, self-limiting conditions, including flu symptoms
and cough. Surprisingly, there is not any overarching official
guidance with respect to the use of THMP in the context of the
pandemic. In principle, THMP would not qualify as therapy for
COVID-19 symptoms as it is considered a severe life-threatening
condition. However, this disease is self-limiting in most of theFrontiers in Pharmacology | www.frontiersin.org 25patients and - in the absence of a positive result in a test –
COVID-19 patients are just ‘flu’ patients and, as such, could self-
medicate with THMP. Several herbal drugs here reviewed have
been registered as THMP. EMA stresses in its guidelines to
healthcare professionals to report all “suspected side effects your
patients experience while infected, regardless of the medicines
intended to treat the disease or pre-existing conditions. Suspected
side effects should be reported even if the medicine is not
authorized for use in COVID-19. When reporting a suspected
side effect in a patient, you should tell us of any other medicines
being taken around the same time, including non-prescription
medicines, herbal remedies, or contraceptives” (EMA, 2020).
We have witnessed how, in different countries, the authorities
have developed an array of tools both to inform and enforce
guidelines: Italian police are acting at retail commerce level by
seizing on the spot any products sold under fraudulent claims; the
Brazilian Ministry of Health is fighting back any misleading claims
with a dedicated channel inWhatsApp (BRASIL, 2020). The case of
France is unique in that its health authorities have provided an
extensive and detailed analysis of the potential interactions of
natural products with either the disease or its clinical treatment
(ANSES, 2020). Finally, many other countries lack the resources to
either reach out to the public in this specific matter or enforce any
significant actions regarding to the sale of such products.
The WHO regional office for Africa has issued a statement
supporting scientifically-driven traditional medicine as “a valid
approach towards the treatment of the virus, as long as their
efficacy and safety are proven through rigorous clinical trials”
(WHO, 2020b), in reaction to a self-proclaimed “COVID-19 herbal
cure”promoted at highgovernmental levels inMadagascar under the
name COVID Organics (CVO) (BBC, 2020; WHO, 2020b).
The potential risks and public impact associated with any
advice on this disease are huge, and understandably; so,
Herbalists associations are more cautious than usual in
promoting herbal medicines in this context. In the UK, the
NMHI just encourages its members to “integrate the herbal
advice they provide with any conventional treatment or
management strategies that are appropriate for their patients,
and to observe the current infection control and management
guidelines formulated by the Department of Health” (NMHI,
2020); and the College of Medicine actively recommends dietary
interventions such as boosting immunity against coronavirus by
‘turning’ to antioxidants and polyphenol-rich food (Dixon, 2020).
General Discussion About the Efficacy of
Reference Drugs and Herbal Medicines in
the Relief of Flu Symptoms in the Context
of COVID-19
Despite the massive use of codeine, paracetamol, and ibuprofen
for the relief of respiratory diseases, the clinical body of evidence
supporting their use in flu is very low. These drugs are mostly
used based on medical experience and clinicians are familiar with
their benefits/risks profiles. These drugs have very common
toxicities and their adverse effects are potentially dangerous in
the context of COVID-19 (Jóźwiak-Bebenista and Nowak, 2014;
Drugs.com, 2020a; Drugs.com, 2020b).September 2020 | Volume 11 | Article 581840
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of both paracetamol and ibuprofen in the treatment of cold/flu
symptoms. As noted in previous sections, clinical evidence is
somewhat higher for ibuprofen than for paracetamol.
General Discussion About the Safety of
Reference Drugs and Herbal Medicines in
the Relief of Flu Symptoms in the Context
of COVID-19
There is quite a consensus in that the patient may safely choose
to use herbal medicines and food supplements in the prevention
of COVID-19. In line with EMA, we advise the patients to keep a
diary of the medication (herbal or not) to informmedical doctors
and other health care professionals in case of hospitalization
worsening of the disease.
Two types of interactions are important in COVID-19: disease-
herbal medicine and herbal medicine-drug interactions. There is a
complicated relationship between the immune system and viral
infections: infection is favored by a weak immune response, whilst
complications arise from an ‘overreaction’ of the immune system
known as “cytokines storm”. As a result, health authorities
discourage any therapies modulating the function of immune
cells in any of both directions -including anti-inflammatory
drugs- and reserve those to clinical management of advanced
stages of COVID-19.
To complicate matters further, a significant fraction of
COVID-19 patients in advance stages may require emergency
treatment consisting of mechanical ventilation under general
anesthesia. It is standard protocol for anesthetists to advise
against taking herbal supplements at least 2 to 3 weeks before
surgery or other procedures requiring anesthesia, due to
potential pharmacodynamic and pharmacokinetic interactions
with these procedures (Levy et al., 2017).
As a result of all the above, the use of any herbal-based
products has been strongly discouraged by medical authorities,
even for typical symptoms of the early stages of COVID-19.
Patients are asked to rest, take paracetamol - if fever is dangerous
only - and plenty of water. Such “Keep calm and carry on”
clinical advice is not realistic and causes dissatisfaction in
patients that are not ready to just ‘sit and suffer’ with the
added distress of the potentially lethal complications. It is all
human that they will try whatever is offered from alternative
medicinal systems to minimize both symptoms and viral load.
Interestingly, there is seldom any mention to anti-tussive
medication, one of the most characteristic symptoms of the
COVID-19 disease, which chiefly contributes to its spread.
Available cough medicines range from OTC products such as
simple linctus (usually containing citric acid in a water-glycerol
base) and THMP (in Europe) to pharmacy/prescription-only
opioids such as dextromethorphan or codeine.
Potential Drug-COVID-19 Interactions
Early clinical data on the evolution of COVID-19 patients
pointed out to a deleterious influence of ibuprofen and
ketoprofen even taken as short as 2–4 days during the onset of
the infection (ANSES, 2020), and prompted French authoritiesFrontiers in Pharmacology | www.frontiersin.org 26to discourage public to use NSAIDs other than paracetamol.
Later data did not clearly substantiate the link between NSAIDs
and worsening of the symptoms, so EMA released a
communication clarifying this point and calling for rational
use of NSAIDs ‘at the lowest effective dose for the shortest
possible period’ (EMA, 2020).
The basis for lower use of NSAIDs has been substantiated on
two lines of thinking: (a) they non-specifically impair the
immune response thus potentially facilitating the viral
infection; (b) some NSAIDs such as ibuprofen, potentially
increase the expression of proteins necessary for the entry of
the virus into the cell. The later includes proteins vimentin
(streptococcus) and ACE-2 (coronavirus).
Surprisingly, paracetamol counts among its many potential
adverse effects “very common incidence” (1% to 10%) of
dyspnea, abnormal breath sounds, pulmonary edema, hypoxia,
pleural effusion, stridor, wheezing, and coughing.
Potential Herbal-COVID-19 Interactions
Herbal Medicines Acting as NSAIDs and/or
Immunomodulators
The French authorities have issued a detailed document warning
against all herbal medicines with anti-inflammatory and
immunomodulatory activities and discouraging their liberal use
if flu symptoms appear, whilst the COVID-19 pandemic is going
on - unless the patient is tested negative (ANSES, 2020).
COVID-19 Interactions With Herbs Modulating Host Cell
Proteins
Coronaviruses have spike or surface (S) glycoproteins giving
them their characteristic shape and name. These help the virus to
enter the host cell by a receptor-mediated process (Lu et al.,
2020). Although they show a complex pattern for receptor
recognition, Angiotensin-converting enzyme 2 (ACE2) is
considered the main host cell receptor of human pathogenic
coronaviruses. In principle, herbal products down-regulating
ACE2 may provide a baseline defense against infection. In the
wake of SARS, Taiwanese researchers described emodin as an
inhibitor of both S and ACE2 proteins. Emodin is present in
medicinal plants such as Rheum officinale Baill. and Polygonum
multiflorum Thunb (Ho et al., 2007).
However, some other plant metabolites have been identified
as potential enhancers of ACE2 expression, including baicalin,
tanshinones, magnolol, curcumin, and rosmarinic acid (ANSES,
2020). Therefore, French authorities have warned that the use of
Scutellaria sp., Magnolia sp., Salvia sp., Curcuma sp., and
Rosmarinus officinalis L., by COVID-19 patients, needs further
evaluation (ANSES, 2020).
Immunomodulators may both stimulate or suppress the
immune system by inhibiting and/or increasing the synthesis
and release of pro-inflammatory mediators, including cytokines
and eicosanoids. There is preclinical evidence of increased IL-1B
and/or IL-18 production in infected immune cells by the use of
Sambucus nigra L., polysaccharide-rich extracts from medicinal
mushrooms, Echinacea angustifolia DC. and Echinacea purpurea
L. (Moench.), Larch (Larix sp.) arabinogalactans-rich extracts,September 2020 | Volume 11 | Article 581840
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(Alschuler et al., 2020).
COVID-19 Interactions With Herbal Medicines Acting as
Antithrombotic
The incidence of venous thromboembolism (VTE) in
hospitalized patients with COVID-19 has been a controversial
matter during the pandemic. Initial studies seemed to point
towards patients the benefits of VTE prophylaxis in emergency
care. Currently, there is insufficient data to recommend for or
against the use of thrombolytics or increasing anti-coagulant
doses in hospitalized COVID-19 patients. More epidemiologic
studies with better control for underlying comorbidities,
prophylactic anticoagulation, and COVID-19-related therapies
are needed (NIH, 2020).
The current recommendation is that anticoagulants/
antiplatelet therapy should not be initiated for the prevention
of VTE in non-hospitalized patients with COVID-19 unless
there are other indications. Similarly, modern phytotherapy
should avoid recommending the use of plants with
anticoagulant effects as prophylaxis of thromboembolic events
triggered by COVID-19 disease. Some of the herbal medicines
here reviewed are known to have anti-coagulant activity on top
of their beneficial effects upon cold/flu symptoms such as garlic
(A. sativum L.) and guaco (M. glomerata Spreng.). Although
caution needs to prevail in assessing whether they are providing a
benefit that outweighs the potential risks in case the disease gets
complicated. This assessment needs to take into consideration
quantitative scientific criteria that, in many times, are lacking. A
case in point is the ‘zero tolerance’ to garlic, despite experimental
evidence showing that an equivalent of 0.6% allicin does not
impair platelet function and does no potentiate platelet-
inhibiting drugs (Scharbert et al., 2007).
Herb-Drug Interactions in the Context of COVID-19
Emergency Treatment
Standard protocols in case of pneumonia contemplate assisted
respiration for long periods, which in turn requires general
anesthesia. Concerns about herb-drug interaction in
anaesthesiology have been historically a major driver for
objections to herbal medicine from clinicians. There is a
substantial body of knowledge of how herbal medicines interact
with anesthesia (Levy et al., 2017; AANA, 2020). There is a
consensus among anesthesiologists in advising against any of the
following herbal medicines that may be taken for flu symptoms:
• Echinacea (Echinacea sp.), because they may (theoretically)
increase the risk of liver damage in patients under anesthesia.
• Ginkgo (Ginkgo biloba L., Ginkgoaceae), St. John’s wort
(Hypericum perforatum L., Hypericaceae), and valerian
(Valeriana officinalis L., Caprifoliaceae) because they may
increase the effects of anesthesia and make it harder to wake
up. They may also cause irregular heart rhythms.
• Ginseng (Ginseng sp., Araliaceae), licorice (Glycyrrhiza
glabra L.), and milk thistle [Silybum marianum (L.)
Gaertn.], because they may cause high blood pressure and a
rapid heart rate.Frontiers in Pharmacology | www.frontiersin.org 27• Garlic (Allium sativum L., Amaryllidaceae), ginkgo, green tea
[Camellia sinensis (L.) Kuntz., Theaceae], feverfew
(Tanacetum parthenium L., Asteraceae), ginger (Zingiber
officinale L.) and Saw palmetto [Serenoa repens (W.
Bartram) Small, Arecaceae], because they may cause
prolonged bleeding.
• Garlic, in addition, can increase the effects of some OTC pain
relievers.
• Ephedra: Several studies and clinical trials have been carried
out to identify drugs that can effectively treat the disease, but,
at the moment, the strategies to deal with the infection are
only supportive (Cascella et al., 2020). Two recent reviews to
on Chinese Herbal Medicine (CHM) can illustrate this. In the
first one, the authors presented some CHM formulae used in
the H1N1 outbreak that can be useful to prevent COVID-19
(Luo et al., 2020). The other offers guidelines for the treatment
of COVID-19, at different stages, using CHM (Ang et al.,
2020a). Among the most cited plant drug, Ephedra plays an
important role. Both indicate a lack of evidence for the
efficacy of those CHM preparations. The presence of a few
medicinal plants such as Ephedra in the suggested guidance
for COVID-19 is a subject of major concerns. Although
Ephedra, listed in the WHO monographs (WHO, 1999), has
been used for the treatment of asthma, cough, cold as well as
in the management of weight loss (its primary use as a
supplement in the USA), globally regulatory agencies have
banned food supplements and medicines containing the
ephedra alkaloid ephedrine, due to the serious adverse
effects especially on the cardiovascular and nervous system
and reported deaths (FDA, 2008; EFSA, 2013; EMA, 2015b).
Benefits/Risks Assessment of Herbal
Medicines Officially Referred as to as
Useful to Relieve Symptoms Related to
Respiratory Conditions
There have been a few metanalyses of the impact of herbal
medicines in the treatment of common flu (Wagner L. et al.,
2015; Ang et al., 2020b). Here, the analysis of the level of evidence
was done considering COVID-19 and the current knowledge
about symptoms and mechanisms of action involved in the
coronavirus infection. In order to support the decision, the
same criteria used for three drugs currently used to mitigate
the same symptoms defined here: fever (paracetamol),
inflammation (ibuprofen), and cough (codeine) were applied to
the selected herbal medicines.
A modified PrOACT-URL approach has been used here as a
tool for the evaluation of herbal medicines. Based on the defined
criterion and the benefits/risks assessment, thirty-six herbal
medicines, and three conventional drugs were evaluated
(Table 4).
The potential usefulness of the herbal medicines in the
management of early symptoms of flu in the context of the
current COVID-19 pandemic was compared with the baseline
benefits/risks assessment performed on the reference drugs
paracetamol (acetaminophen), ibuprofen and codeine. These
drugs resulted not to be backed up by robust clinical evidence,September 2020 | Volume 11 | Article 581840
TABLE 4 | Benefits/risks assessment in adult patients without any other conditions suffering early/mild flu symptoms in the context of COVID-19.
Overall Benefit Adverse Effects2 Overall Safety Benefits/Risks
Fever
High B-II Mediuma Promising
High A-IV High Positive
High D-III Medium Promising
High A-Ic High Positive
Low A-IV High Unknown
High D-IV Medium Promising
Low D-IV Medium Unknown
High D-IV Medium Promising
Medium A-IV High Promising
Low A-IV High Unknown
IV Low A-IV High Unknown
High A-II High Positive
High A-Ic High Positive
High B-IV Medium Promising
Medium C-III Medium Promising
Low A-IV High Unknown
High C-IV Medium Promising
IV Low A-IV High Unknown
High D-IV Medium Promising
IV High C-IV Medium Promising
IV Low A-IV High Unknown
Low A-III High Unknown
Low A-IV High Unknown
Low A-IV High Unknown
Low A-III Medium Unknown
Low B-III High Unknown
IV High C-IV Medium Promising
High A-Ic High Positive
IV Low C-III Medium Unknown
IV Low A-Icb High Unknown
Low A-IV High Unknown
Low A-IV High Unknown
Medium B-II Medium Promising
Medium B-II Medium Promising
Low E-Ib Low Negative
Low E-Ib Low Negative
bert et al., 2007); (b) Chronic administration of products with 7%–8% silymarin content are safe
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28Treatment Evidence Levels in Respiratory conditions1
Plant Species/Drug Pharmacopoeial name Cold Flu Bronchitis Asthma Cough Pain
Allium sativum/bulbs, powder Allii sativi bulbus (EMA) Ib
Althaea officinalis/roots, leaves Althaeae radix Ib
Andrographis paniculata/leaves Andrographidis paniculatae folium Ib Ib Ib
Commiphora molmol/gum Myrrha gummi-resina 1b
Cymbopogon citratus/leaves Cymbopogonis folium IV IV
Echinacea angustifolia/roots Echinaceae angustifoliae radix Ib Ib
Echinacea pallida/roots Echinaceae pallidae radix IV IV
Echinacea purpurea/herb Echinaceae purpureae herba Ib Ib
Eucalyptus globulus/essential oil Eucalypti aetheroleum III III
Eucalyptus globulus/leaves Eucalypti folium IV IV
Foeniculum vulgare/fruits Foeniculi amari/dulcis fructus IV IV
Glycyrrhiza glabra/roots Liquiritiae radix Ib
Hedera helix/leaves Hederae helicis folium Ib Ib Ib
Justicia pectoralis/leaves Justicia pectoralis folium Ib
Magnolia officinalis/bark Magnoliae cortex III
Malva sylvestris/leaves Malvae sylvestris folium IV
Mikania glomerata/leaves Mikania glomerata folium Ib IV
Ocimum gratissimum/leaves Ocimi Sancti folium IV IV IV IV
Pelargonium sidoides/roots Pelargonii radix Ia Ib Ib
Pimpinella anisum/fruits essential oil Anisi aetheroleum/fructus Ib IV
Plantago lanceolata/leaves Plantaginis lanceolatae folium IV IV
Platycodon chinensis/roots Platicodi radix IV
Polygala senega/roots Polygalae radix IV IV
Polypodium vulgare/rhizome Polypodii rhizoma IV
Potentilla erecta/rhizome Tormentillae rhizoma IV
Primula veris/roots Primulae radix IV
Salix sp./bark Salicis cortex IV IV Ib
Sambucus nigra/fruits Sambuci fructus Ia Ia
Scutellaria baicalensis/roots Radix Scutellariae IV
Silybum marianum/fruits Silybi mariani fructus
Thymus vulgaris/herb essential oil Thymi herba/aetheroleum IV
Tilia cordata/flowers Tiliae flos IV
Zingiber officinale/rhizome Zingiberis rhizoma IV IIa* IV IV
Ibuprofen – Ia IV Ia
Codeine – IV
Paracetamol – IV IV
(1) Grading as per Table 1;(2) Codes and Grading as per Table 2;(3) As per Table 3; (a) Products with less than 0.6% allicin content are safe (Schar
up to 40 months (Corchete, 2008); (*) Clinical experiment in SARS patients (Vahdat Shariatpanahi et al., 2013).
Silveira et al. COVID-19 and Evidence-Based Phytotherapyand their safety profile was concerning in some cases. According
to this ‘baseline’, five herbal medicines were found as potentially
valid candidates in managing early or mild symptoms of cold, flu
and bronchitis in the context of COVID-19 as they provide with
ample safety margins and good evidence for efficacy: Althaea
officinalis, Commiphora molmol, Glycyrrhiza glabra, Hedera
helix, and Sambucus nigra. The authors recommend starting
their integration into clinical advice as adjuvant therapies for
respiratory diseases, even in the context of COVID-19.
A second group of twelve herbal medicines is to be considered
as promising candidates, due to their reasonable safety margins
and emerging evidence for efficacy: Allium sativum, Andrographis
paniculata, Echinacea angustifolia, Echinacea purpurea,
Eucalyptus globulus essential oil, Justicia pectoralis, Magnolia
officinalis, Mikania glomerata Pelargonium sidoides, Pimpinella
anisum, Salix sp, and Zingiber officinale. The authors recommend
the scientific community to prioritize working on these herbals
towards their full integration into clinical use. These two groups
are, in the opinion of the authors, comparable in terms of safety
-and sometimes efficacy- with the three reference drugs currently
in clinical use for the target symptoms, so these herbal medicines
may help to mitigate the discomfort in the early stages of the
disease, based on their anti-inflammatory, immunomodulatory,
and antitussive properties.
The following plants have good evidence for the treatment of
asthma: Glycyrrhiza glabra, Magnolia officinalis, Mikania
glomerata, and Pimpinella anisum. These plants cannot be
candidates to treat respiratory infections but may be safe to use
if the asthmatic patient suffers flu symptoms.
The rest of herbal medicines (approximately half of the
analyzed herbal medicines) appear to have a good safety
profile, but simply there is not enough evidence – clinical or
pre-clinical – about their action on the target symptoms (cough,
fever) or conditions (cold, flu). Therefore, they must be
categorized as of ‘unknown’ potential and would need much
more research to build up the necessary evidence to justify their
use in the management of flu, let alone in the context of
COVID-19.
Benefits/Risks Assessment of Herbal
Remedies Not Covered by International
Monographs
Several food/herbal-based remedies are associated with the
treatment of common cold and flu because they include
vitamins (such as lemon juice), aromatic principles with
perceived benefits for the upper respiratory system (such as
mint, bayleaf), or because they are culturally considered as a
“cure-all” (such as Nigella). Some of them are presented to the
public in a “pharmaceutical forms” (capsules, tablets, syrups),
thus looking like a “safe and effective medicinal approach”. The
regulatory status of these products varies from country to
country, and we advise here that only products that are
regulated as (herbal) medicines should be used since this is an
essential requirement for a product’s safety.
The following herbals and foods were identified by the
authors as falling into this category: Citrus limon, CulcitiumFrontiers in Pharmacology | www.frontiersin.org 29canescens, Laurus nobilis, Lippia graveolens, and Plectranthus
amboinicus. We subjected the evidence for the efficacy and safety
of these plants to the same Benefit/Risks assessment applied to
the “officially recognized” herbal medicines, and the collected
preclinical, clinical, and safety data are provided.
Nigella may be considered as a borderline “promising”
treatment example as there is some preliminary clinical
evidence for its relief of cough but it seems to be restricted to
asthma patients, so from a physiopathological point of view is
not clear how useful it would be in cold/flu. As for the others,
although considered safe, there is simply not enough evidence –
clinical or pre-clinical – in relation to their benefits on the target
symptoms (cough, fever) or conditions (cold, flu).
Despite their lack of evidence in the treatment of flu, lemon,
bay leaves, mint, and Nigella are deeply ingrained ‘polyvalent’
remedies in many cultures all over the World. Therefore, a
succinct discussion on their efficacy and safety in the treatment
of respiratory conditions is essential:
• The juice or tea of Citrus limon (L.) Burm.f fruits, alone or
associated with salt, honey or ginger has been used to relieve
cough and fever related to flu and cold in several traditional
systems (Papp et al., 2011; Panizza et al., 2012; Sultana et al., 2016;
Klimek-Szczykutowicz et al., 2020). However, there is no clinical
evidence of such action in the respiratory tract, although this
species is well-known as a rich source of vitamin C (Ye, 2017).
• Besides the use as food, the decoction of Laurus nobilis L.
dried leaves is taken orally to treat respiratory distress
(Chevallier, 1996; Ross, 2001), and the only information on
L. nobilis posology is given by the American Pharmaceutical
Association (Duke et al., 2002). The closest to an applicable
study is an in vitro study examining SARS-CoV and the effect
of several essential oils (Chen et al., 1995). The essential oil of
L. nobilis leaves was also evaluated for its antinociceptive and
anti-inflammatory activities in mice and rats (Sayyah et al.,
2003). However, the lack of clinical evidence led to concerns
about the use of this species.
• Mentha x piperita L. (peppermint) is widely used to treat
bronchitis, fever and other respiratory disorders (WHO, 2002;
Blumenthal, 2003), although no evidence can be found to
corroborate these actions. The essential oil contains, among
other compounds, menthol, menthone, menthofuran, and
pulegone, a well-known hepatotoxin (Engel, 2003), leading
to a deep concern about the use of essential oil (EMA, 2016e).
However, peppermint tea usually contains a small amount of
these compounds, and the normal use rarely led to serious
adverse effects (EMA, 2008a).
• Nigella sativa L. (black seeds) is globally known as a spice and
as a food item. In Arabic medicine, this species has very high
status as a herbal medicine used for a wide range of diseases.
In the context of COVID-19, the relevant uses are for asthma
and in the more general management of inflammatory
conditions. With regards to respiratory diseases its use can
be traced back at least to Avicenna (ca. 980 – 1037, C.E.), who
indicated it for shortness of breath and for stopping phlegm
and Imam Ibn Qayyim Al-Jawziyya (1292–1350 C.E.), whoSeptember 2020 | Volume 11 | Article 581840
Silveira et al. COVID-19 and Evidence-Based Phytotherapyrecommended it for gasping and hard breathing (Koshak
et al., 2018). In many Arabic Countries, “black seed” is used
for asthma and cough, among many other uses, especially of
gastrointestinal diseases (like abdominal pain, stomach ache,
colic), rheumatism, skin diseases and recently use to manage
diabetes have become popular (Aisa et al., 2019). Some small
studies demonstrate clinical benefits in asthma patients
(Koshak et al., 2017). Although black seed may be useful in
the symptomatic relief of respiratory symptoms, especially
associated with the severe asthmatic cough, the clinical
evidence is very limited. A particular concern, in this case,
are the many well-intended but very low-quality studies and
the broad range of claims they try to support, making any
assessment problematic.Limitations of the Present Work
The authors are aware of the limitations of this assessment: first,
the body of studies is not large, even for reference drugs, and this
is further complicated by the uncharted territory, which is the
current pandemic. Second, the decision-making framework is
here applied to herbal medicines for the first time and would
need external validation.
The PrOACT-URL method is a valid approach to inform
decision-making at high regulatory levels. The way we apply it
here may well attract the critique of experts in the field of
evaluation of the benefits/risks balance for medicines. We
welcome constructive comments since this is exactly what we
pursue: to start a high-level discussion on the potential of herbal
medicines for the management of flu and their safety
implications during this pandemic. For this, we need to work
towards further adapting decision-making frameworks to bring
about advances in ‘clinical phytotherapy’.
We acknowledge that the selection of herbal medicines is
geographically limited and that many other species could have
been considered. We took a “legalist” approach by only accepting
entries provided by EMA or WHO, and we recognize we hold a
collective expertise, especially in European and American herbal
medicines. Nevertheless, the list includes globally-recognized,
therapeutically relevant herbs. At the same time, there is, clearly,
an emerging body of evidence on specific Asian (often
multiherbal) preparations (especially TCM), which also is
included in this Research Topic of Frontiers in Pharmacology,
Sect. Ethnopharmacology, and thus these studies mutually
complement each other.CONCLUSIONS
A total of 39 herbal medicines were identified as very likely to
appeal to COVID-19 patients. According to our method, the
benefits/risks assessment of the herbal medicines was found
positive in 5 cases, promising in 10 cases, and unknown for the
rest. On the same basis, only ibuprofen resulted promising, but
we could not find compelling clinical evidence for a positiveFrontiers in Pharmacology | www.frontiersin.org 30assessment to endorse the adjuvant use of paracetamol and/or
codeine due to their common adverse effects in the
respiratory function.
Our work suggests that Althaea officinalis, Commiphora
molmol, Glycyrrhiza glabra, Hedera helix, and Sambucus nigra
have safety margins superior to those of reference drugs and
enough levels of evidence to merit their potential clinical use as
adjuvants in the treatment of early/mild cases of COVID-19.
Herbal medicines are not a “magic bullet” to solve the
problems related to flu - let alone COVID-19 or any other
coronavirus - neither can avoid the virus infection but may
alleviate symptoms and potentially improve the general
wellbeing of patients. It requires a careful assessment of
whether such adjuvant therapies are justified or not. Then
again, it can only be a suitable therapy at a stage when the
severity of the disease is minor. Overall, we highlighted the
potential of some medicinal plants for the adjuvant management
of early symptoms of flu within the context of COVID-19 in
otherwise healthy adults. For an herbal medicine to be a
medicine high quality, chemically well-characterized, and
pharmacologically well-studied preparations are acceptable
only. Equally, it will be essential that such well-characterized
preparations are used in all future pharmacological and clinical
studies (Heinrich et al., 2020).
In a broader context, this study also offers a novel approach
for assessing the risks and benefits of using herbal medicines.
Since the PrOACT-URL strategy is used here for the first time
with a set of herbal medicines, we want to highlight the
opportunities for a rigorous and evidence-based approach will
have in a balanced assessment of such medicines.AUTHOR CONTRIBUTIONS
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Farmacoterápico Latino S.A).
Ali, M., Sahrawat, I., and Singh, O. (2004). Volatile Constituents of Cymbopogon
citratus (DC.) Stapf. Leaves. J. Essent. Oil-Bear Plants 7, 56–59. doi: 10.1080/
0972-060X.2004.10643365
Ali, B. H., Blunden, G., Tanira, M. O., and Nemmar, A. (2008). Some
phytochemical, pharmacological and toxicological properties of ginger
(Zingiber officinale Roscoe): A review of recent research. Food Chem.
Toxicol. 46, 409–420. doi: 10.1016/j.fct.2007.09.085
Al-Jawad, F., Al-Razzuqi, R., Hashim, H., and Al-Bayati, N. (2012). Glycyrrhiza
glabra versus Boswellia carterii in chronic bronchial asthma: A comparative
study of efficacy. Indian J. Allergy Asthma Immunol. 26, 6–8. doi: 10.3923/
ijp.2018.1072.1079Frontiers in Pharmacology | www.frontiersin.org 31Al-Jenoobi, F. I., Ahad, A., Raish, M., Al-Mohizea, A. M., and Alam, M. A. (2015a).
Investigating the Potential Effect of Commiphora myrrha on the
Pharmacokinetics of Theophylline, a Narrow Therapeutic Index Drug. Drug
Res. 65, 312–316. doi: 10.1055/s-0034-1382032
Al-Jenoobi, F. I., Alam, M. A., Al-Mohizea, A. M., Ahad, A., and Raish, M.
(2015b). Orally co-administrated oleo-gum resin ofCommiphora myrrha
decreases the bioavailability of cyclosporine A inrats. Pharmazie 70, 549–
552. doi: 10.1691/ph.2015.5551
Alschuler, L., Weil, A., Horwitz, R., Stamets, P., Chiasson, A. M., Crocker, R., et al.
(2020). Integrative considerations during the COVID-19 pandemic. Explore
(NY). doi: 10.1016/j.explore.2020.03.007
Al-Snafi, A. E. (2018). Pharmacological and therapeutic activities of Hedera helix-
A review. IOSR J. Pharm. 8, 41–53.
Amaral, A. C. F., Rodrigues, A. G., Ribeiro, J. E. G., DSantos, M. G., and Netto
Junior, N. L. (2006). A Fitoterapia no SUS e o Programa de Pesquisas de Plantas
Medicinais da Central de Medicamentos (Brasilia: Ministério da Saúde).
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Programa Estadual de Fitoterapia (Fortaleza: Secretaria de Saúde do Estado do
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tratamento da tosse e sintomas respiratórios: um ensaio clıńico randomizado
(Universidade Federal do Ceará: MSc Dissertation).
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F. V., Bonjardim, L. R., et al. (2011). Citral reduces nociceptive and
inflammatory response in rodents. Braz. J. Pharmacogn. 21, 497–502.
doi: 10.1590/S0102-695X2011005000065
Rabelo, M., Souza, E. P., Soares, P. M. G., Miranda, A. V., Matos, F. J. A., and
Criddle, D. N. (2003). Antinociceptive properties of the essential oil ofOcimum
gratissimum L. (Labiatae) in mice. Braz. J. Med. Biol. Res. 36, 521–524.
doi: 10.1590/S0100-879X2003000400016
Rainsford, K. D. (2015). “Pharmacology and Toxicology of Ibuprofen,” in
Ibuprofen. Ed. K. D. Rainsford (Chichester: Wiley Blackwell), 132–236.
doi: 10.1002/9781118743614.ch5
Rajagopal, S., Kumar, R. A., Deevi, D. S., Satyanarayana, C., and Rajagopalan, R.
(2003). Andrographolide, a potential cancer therapeutic agent isolated from
Andrographis paniculata. J. Exp. Ther. Oncol. 3, 147–158. doi: 10.1046/j.1359-
4117.2003.01090.x
Ramirez, J.-K., Velasquez-Arevalo, S., Rodriguez, C. N., and Villarreal-La Torre,
V. E. (2020). Culcitium canescens Humb. & Bonpl. (Asteraceae): una
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Sidibé, L., Chalchat, J.-C., Garry, R.-P., Lacombe, L., and Harama, M. (2001).
Aromatic Plants of Mali (IV): Chemical Composition of Essential Oils of
Cymbopogon citratus (DC) Stapf and C. giganteus (Hochst.) Chiov. J. Essent.
Oil Res. 13, 110–112. doi: 10.1089/jmf.2008.0281
Sidor, A., and Gramza-Michałowska, A. (2015). Advanced research on the
antioxidant and health benefit of elderberry (Sambucus nigra) in food – a
review. J. Funct. Foods 18, 941–958. doi: 10.1016/j.jff.2014.07.012
Silva, F. F. M., Moura, L. F., Barbosa, P. T., Fernandes, A. B. D., Bertini, L. M., and
Alves, L. A. (2014). Analysis of chemical composition of the essential oil of holy
grass (Cymbopogon citratus) obtained through extractor for water vapor trail
with built with materials of acquisition and easy low cost. Holos 30, 144.
doi: 10.15628/holos.2014.1762
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